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EBV infects at least 95% adult population worldwide and is linked to a number of 
malignancies, such as Hodgkin's disease, B cell lymphoma, T cell lymphoma and 
nasopharyngeal carcinoma (NPC). There is significant interest in exploiting the 
HLA class I-restricted CD8+ T cell response to EBV target antigens as a means of 
developing immunotherapeutic approaches to EBV malignancies' treatment. 
However，HLA polymorphism forms a significant challenge in the design of global 
vaccine; exploring the epitope choices to EBV viral antigens under specific HLA 
polymorphism is thus helpful for the development of epitope-based therapy to EBV 
relevant diseases. Such therapy should hold particular value in the treatment of NPC 
which is a prevalent disease amongst Southern Chinese. 
Response restricted through HLA-Al 1，a very frequent allele in Southern Chinese, are 
particularly interesting to study because Chinese EBV strains are frequently variant in 
two EBNA BB-derived eptiopes, IVT and AVF, that induce immunodominant 
responses in All-positive Caucasian donors. The question is whether these variant 
epitope sequences are immunogenic or silent in Chinese donors. Using Elispot 
analysis on Hong Kong donors, only 1 out of 116 donors has a response to IVT and 
12 out of 117 donors recognize AVF. The data indicated almost all of IVT and AVF 
variants are unlikely to induce non-CTLs response in vivo. Thus again emphasis 
that it is possible the variants may have evolved as immune escape mutants that enjoy 
the selected advantage in the hosts. A2 subtype polymorphism also may influence 
the epitope choice and it is interesting to study this in Chinese people because A2 
subtype distribution is much wider there than in Caucasions. Our results of Elispot 
assay showed that most A2 restricted epitopes responses are relatively weak and rare 
in the A2 restricting donors, suggesting that they are highly subtype specific, there are 
no pan A2 epitopes except possibly an EBNAl -derived epitope，VLK. In contrast, 
Non-A2 and Non-Al 1 restricted epitopes, such as WTL, VSF, VMS, and PYL, have 
much higher frequencies of responses in Chinese than would be predicted from the 
expected from the representation of their known restricting alleles in the Chinese 
population, suggesting that these are presented by related Chinese HLA class I alleles 
that are within the same HLA supertype family. 
On the context of NPC，SSCS，TYG, lED, FLY, LLW, RRRW are relatively good 
candidates for vaccine. Supertype peptides, WTL, VMS, PYL, are ideal candidates 
to cover the relatively rare HLA donors in Southern Chinese. On the context of NPC, 
SSCS, TYG, lED, FLY, LLW, RRRW are relatively good candidates for vaccine. 
Supertype peptides, WTL, VMS, PYL, are ideal candidates to cover the relatively rare 













在針對鼻煙癌表位治療的意義上，SSCS, TYG, TED, FLY, LLW, YLQ, RRRW 
是相對較好的候選表位，而一些超表位，WTL, VMS, PYL則是理想的候選 
著來覆蓋一些人群中少見的HLA表型。 
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1 Chapter 1 Introduction 
1.1 Epstein-Barr (EBV) Virus 
EBV, a lymphotropic gamnm-herpesvirus, was first reported inl964 in a cultured 
Burkitt lymphoma (BL) cell line [1], It is a member of herpes viridae family, more 
than 90% of the world's adult population are persistently infected with the virus 
[2]. 
1.1.1 Virus Structure and Genome Structure 
EBV is a classic example of a genetically stable DNA virus. It has a toroid-shaped 
protein core that is wrapped with DNA, a nucleocapsid with 162 capsomeres, a 
protein tegument between the nucleocapsid and the envelope, and an outer 
envelope with external glycoprotein spikes. The major EBV capsid proteins are 
160, 47, and 28 kDa. The most abundant EBV envelope and tegument proteins are 
350/220 and 152 kDa, respectively [1], 
The DNA of the virus is a linear and double-stranded; the genome of EBV is 
composed of 172 kb [2]. The predominant intracellular form of the viral DNA is 
episomal and circular. The sequence of "standard" strain, B 95.8, which was 
obtained from a patient with infectious mononucleosis and passaged in marmoset 
leucocytes [3], has been determined to be 172,281 nucleotide pairs long [4], 
B95.8 DNA has been completely cloned in PBR322 and Charon 4A[5]. The DNA 
consists of direct tandem repeats of a 3X1O^ dalton sequence at both ends (TR); a 
long unique region of 8X10^ daltons (UL); a short unique region of 9X10^ daltons 
1 
Chapter 1 Introduction  
(US); and direct tandem repeats of a 2X10^ dalton sequence (IR), which joins UL 
and US. 
Figure 1-1 EBV genome structure 
Expert Reviews in Molecular Medicine (Murray PG, 2001): http://www-
ermm .cbcu.c am .ac.uk 
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1.1.2 Virus Types 
There are type 1 and type 2 EBV virus strains now also referred to as EBV-1 and 
EBV-2 or types A and B with overall similarity in structure and bio-reactivity. 
Type-specific polymorphisms exist in the latent genes that encode EBV nuclear 
antigens (EBNA), EBNA2, EBNA3A, 3B, 3C [6，7] which result in amino acid 
sequence difference of 16%, 20%, 28%, and 47% respectively between the EBNA 
proteins in two types of virus [8]. 
2 
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EBV has shown markedly different frequencies of infection by the two types in 
different geographical locations [9，10]. Type 1 is prevalent in most areas in the 
world. But in some area such as Africa and Papua New Guinea, almost half of 
people carry type 2 viruses. In some situations, such as HIV-positive subjects, the 
occurrence of EBV type 2 infections was much higher than in the general 
population [11]. Coinfection with type A and B is often found in immunosupressed 
individuals, but rarely in healthy carriers [12，14，15]. 
In the 1 aboratory, B95.8 v irus is the p rototype I s train. Of the o ther 1 aboratory 
strains, P3HR-1 (type2) is a clone of Africal Burkitt tumor lymphocytes [12] and 
W91(typel) is a cell line established by infecting marmoset lymphocytes with a 
vims derived from an African Burkitt tumor[13], and AG876 (type 2) is an African 
Burkitt tumor cell line[18]. 
1.2 EBV Infection and malignancies 
1.2.1 In Vitro Infection 
EBV infection of B lymphocytes leads to immortalization of the cells into 
laboratory-infected lymphoblastoid lines, in some cells, if is possible to induce 
activation of the latent virus into lytic cycle, leading to cell death with the 
production of infectious virions [1]. The stages of EBV infection are defined in 
vitro by the detection of antigen expression in cells. These antigens are: EBV 
nuclear antigen (EBNA); early antigen (EA); virus capsid antigen (VCA)， 
membrane antigen (MA) [19]. 
EBV Nuclear Antigen: EBNA is a complex of six distinct nuclear proteins, 
EBNAl, 2，3A, 3B, 3C, and leader protein (EBNA -LP), an alternative 
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nomenclature also in current use designates the EBNA family as EBNA 1, 2, 3, 4, 
and 6, and EBNA-5/LP [20]. The functions of these proteins are listed in Table 1. 
Latent Membrane Protein: LMP I was defined from the nucleotide sequence 
encoded by BNLFl; it is a 62-kDa-membrane protein containing a cytoplasmic 
amino terminus of 23 residues, six membrane-spanning segments, and a 
cytoplasmic carboxy terminus of 200 residues. LMP2 can be divided into LMP2A 
and LMP2B, their structures are similar,the first exons of LMP2A and LMP2B are 
the only unique exons, the first LMP2A exon encode 119 amino acid cytoplasmic 
N-terminal domain. And the first LMP2B exon is short and lacks methionine 
codon. All other exons are shared by LMP2A and 2B, and encoded 12 
hydrophobic integral membrane sequences separated by short reverse truns and a 
27 amino acid hydrophilic carboxy-terminal domain. [14:. 
Early Antigen: EA is a complex of immediate-early and early viral protein, 
including BZLF I, BALF2, BHRFl, BMRFl，and BMLFl. It is an antigen 
complex expressed in the early phase of the EBV lytic cycle before the viral 
replication [15，16]. 
Virus Capsid Antigen: VCA appears following the replication of viral DNA and 
is a complex of proteins expressed in cycle including complex of the virion, It was 
the first detected EBV antigen [24]. Anti-VCA antibodies only reacted with naked 
virus particles [17], establishing that the antigen is a structural component of the 
vims capsid. VCA components as prsent in both the nucleus and cytoplasm. 
Membrane Antigen: MA was first detected in 1966 [18]. It is a complex ofEBV-
cooled membrane proteins, including a glycoprotein of molecular weights 350kDa 
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(gp350), the most abundam viral envelope protein, which is a target for 
neutralising antibody responses. 
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Table 1 EBV latent genes and functions 
The table below is summarized from [3，21, 27-29] 
Latent Function 
genes 
EBNA-1 Binding to origin of replication (Ori P)，initiates replication and 
keeps EBV genome as an episome. 
EBNA-2 Essential for immortalization; Transactivation of LMP1，LMP 2， 
CD21, CD23; Target of EBV CTL. 
EBNA-3A Essential for immortalization (uclear function); Target of EBV CTL. 
EBNA-3B Non-essential for immortalization, Targets of EBV CTL. 
EBNA-3C Essential for immortalization (uclear function); Target of EBV CTL. 
EBNA-LP Required for efficient immortalization. 
LMP-1 Essential for immortalization. Malignant trasformation of rodent 
fibroblasts in vitro, activation of CD23, CD39，CD40，up-regulation 
of CD54 and BCL-2 family members, inhibition of epithelial 
differentiation, target of EBV CTL. 
LMP-2A Non-essential for immortalization, inhibition of calcium mobilization 
by surface immunoglobulin stimulation 
LMP-2B Non-essential for immortalization; modulator of LMP2A (?). 
1.2.1.1 Latent Infection 
In 1 atent infection, the v irus maintains i ts genome within the c ell and expresses 
only a limited set of genes without producing progeny virus or destroying the cells. 
Resting memory B cells are thought to be the site of persistence in vivo [30]. In 
vitro EBV infection induces B cell transformation into proliferating lymphoblasts 
the process is called immortalization. When only the 9 latent genes expressed to 
produce six EBNAs and three LMPs (LMPl, 2A, 2B) [14，19]. The combination 
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of expressions of these latent genes varies in different disease and can be classified 
into three latency states (Table 2). 
Latency III: In vitro, lymphoblastoid cells lines (LCLs) established by EBV 
immortalizing the primary resting B cells, the cells generally carry several copies 
of the viral genome in an episomal form and express only a restricted number of 
gene products which we call the “latency III” pattern. The pattern is consisted of 
six nuclear antigens (EBNAs 1, 2, 3A, 3B, and 3C, and the leader protein, EBNA-
LP), three latent membrane proteins (LMPs 1，2A and 2B) and two small RNAs 
known as the EBERs. 
Latency II: Latency II is found in nasopharyngeal carcinoma (NPC) and 
hodgkin's disease (HD), vims-infected tumor cells express LMPs, EBERs, and 
BamA RNAs accompanying the expression of EBNAl. 
Latency I: Latency I is found in BL, the virus infected tumor cells characterized 
by expression are EBERs, BARFO ORF, the only viral protein product is EBNAl. 
Table 2 Latency type and EBV protein 
Latency Type Gene expression 
1 — EBNAl, ±LMP2a, BamA RNAs 
II EBNAl, LMP1, LMP2a, BamA RNAs 
III EBNAl, 2，3a，3b, 3c, LP; LMPl and LMP2, BamA RNAs 
7 
Chapter 1 Introduction   
1.2.1.2 Lytic Infection 
In vitro, virus replication is always from inducing latently-infected cells into lytic 
cycle, leading to production of progeny virus in up to 10% cell, that is, no evidence 
shows that EBV infection leads directly into a fully productive lytic infection in 
vitro [20:. 
In vivo, the permission host cell has not been identified yet; but infection of 
epithelial cells usually leads to complete viral replication resulting in cytolysis [20] 
indicating that epithelial cells may be the natural permissive cell in the body. The 
EBV encoded protein, Z (also called Zta, ZEBRA or BZLFl protein), plays a 
dominant role in the switch from latent cycle to productive infection [21, 22]. 
Viral lytic cycle can.be induced by superinfection with P3HR1EBV [23], addition 
of chemical inducers [36, 37] or by transfector with the BZLFl gene that encodes a 
40-kDa nuclear protein [24]. Replication is associated with the expression of a 
large number of proteins (up to 80), these proteins can be classified into three 
temporal phases: immediate early, early, and the late [1] including early 
membrane antigen (EMA) [39], early intracellular antigen (EA)[23, 25, 26] late 
viral capsid antigen (VGA) [27] and late membrane antigen (LMA) [28]. 
1.2.2 Infection in the Natural Host 
1.2.2.1 Primary Infection 
Primary infection usually occurs in childhood in the world but with another peak 
of primary infection occurring at ages 14-20 in Caucasians [29]. Primary infection 
is usually asymptomatic, but 30-50% of cases in the West in adolescence cause 
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infectious mononucleosis (IM) [43]. The disease is most often a mild, self-limiting 
illness followed by lifelong virus latency, this results in 80-90% of adults 
worldwide being seropositive and containing to carry the vims [43:. 
The primary target cell for EBV infection, whether epithelial or B cells, has long 
been controversial. EBV is shed from lytically-infected cells in the oropharynx, 
with latent virus infection in a fraction of B cells (figure 1-3), Acute IM (AIM) 
occurs after 30-50 days incubation period, and presents with the symptoms of sore 
throat and fatigue and substantial functional impairment. Objective physical and 
laboratory examination findings included pharyngitis, cervical lymphadenopathy, 
and a moderate absolute and atypical lymphocytosis mainly due to activated T 
cells reached to the life [29]. Isolates were identical from saliva and blood in same 
individual [30] [45]. Now the consensus conclusion is that virus infection involves 
two cellular compartments, one is the B cell which is the main mediator of primary 
and persistent latent infection, another is an epithelial cell in which the infection is 
predominantly lytic [31][46]. Studies [32] have shown that there are three possible 
pathways for EBV to penetrate epithelial barriers and enter into the B cell 
compartment of the oropharyngeal mucosa. First, EBV could be capable of 
crossing intact epithelial layers by transcytosis, and subsequently infecting B cells 
in the underlying lymphoid tissue of the tonsil Secondly, EBV could infect B 
cells stationed in the lymphoepithelium. Thirdly, crypt M cells could deliver EBV 
to the lymphoid tissue beneath the tonsil surface. 
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1.2.2.2 Persistent Infection 
Following primary infection, EBV persists in B-lymphocytes for life in vivo 
(figure 1-2); When a B cell is first infected, the lymphoblastoid form of latency III 
is established with expression of the whole spectrum of the latent gene products [3: 
(table 2)，but this followed by downregulation of viral genes and viral persistence 
in r esting c ells. Under certain conditions, these c ells r eact weak t o 1 ytic c ycle, 
gaining the low level of continuous or intermittent production of infectious virus 
“ into saliva which may again infect epithelial cells [49]. In normal virus carriers, 
each individual viral load remains fairly constant at around 5-500 vims infected 
cells in every 1x10^ circulating B cells [50], and the numbers within a person 
remain stable over many years [30, 51'. 
Figure 1-2 EBV infection model 
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1.2.3 Malignancies Associated with EBV 
EBV has been found in a variety of malignancies; the virus is now estimated to be 
present in around 96% Endemic Burkitt's lymphoma (BL) [33]. Besides BL，EBV 
is also associated with B-lymphoproliferative disease in the immunocompromised 
host [34], subsets of Hodgkin's lymphoma [54] and certain types of T-cell 
lymphoma [35]. The virus also presents in 100% undifferentiated nasopharyngeal 
carcinoma (NPC) [36] and 10% of stomach cancers [57:. 
Endemic Burkitt's Lymphoma (BL) is a high-grade malignant lymphoma of 
small, noncleaved B cells, which occurs predominantly in the malaria belts of 
central Africa and in New Guinea where the tumor affects mostly children, often 
presenting as a B cell tumor in the jaw. Epidemiologic studies suggest that EBV 
may have a causal role in the development of the disease because patients show 
elevated titers of antibody to EBV structural proteins [58] and EBV-specific DNA， 
RNA and gene products can be found in all biopsies of the lymphoma [33]. Now it 
is recognized that the virus-infected tumour cells only express EBNAl protein 
[59]. 
Immunoblastic Lymphoma: this malignancy is often referred to as post-
transplantation lymphoproliferative disease (PTLD). Over 85% of cases of PTLD 
are of B cells origin [37] and arise because of long-term immunosuppression 
therapy. Under that condition, the balance between immune surveillance and viral 
latency is broken, resulting in inadequate T-cell control of latent EBV. 
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The disease was initially described in 1969 in renal transplant patients [38]. It is a 
common complication of bone marrow and solid-organ transplantation when 
PTLD risk is already related to the intensity of immunosupression [62-64 . 
The disease expresses the full spectrum of EBV latent proteins in tumor cells [39:. 
Suggesting that EBV transformation is the key drives of proliferation[40, 41]. 
However, the mechanisms leading to malignant transformation are not fully 
known, it is likely that the continual proliferation of EBV-infected B-cells, with 
levels of EBV copy numbers rising to 500,000 per 10^ peripheral blood 
lymphocytes, would increase the chance of random genetic damage [65:. 
Hodgkin,s Lymphomas (HD): H D is an unusual 1 ymphoma with a malignant 
population of mononuclear Hodgkin and multinuclear Reed-Sternberg (H-RS) 
cells within a reactive infiltrate of nonmalignant cells, which are characteristic of 
the different subtypes of Hodgkin's lymphomas. The disease has a prevalence of 
2-4 per 100，000 individuals in the UK and USA. The tumor is the most common 
lymphoma in young people, accounting for around 20% of all lymphoma in the 
western world [42], another incidence peak is in the middle to old age [43:. 
The malignant cells of the disease are H-RS, cells are surrounded by a heavy 
infiltrate of reactive mononuclear cells, which make up the bulk of tumor tissue. 
The H-RS cells are derived from B-lymphocytes [44]. HD can be classified into 
five histological subgroups according to the morphology under the microscope: 
lymphocyte predominant, mixed cellularity, nodular scelerosing, lymphocyte rich 
classical, and lymphocyte depleted [45]. Of these, the lymphocyte predominant 
form of the disease is now considered non-EBV associated, while mixed cellularity 
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and lymphocyte depleted subtypes have strongest association with the EBV [42, 
46’ 47]. 
Patients with a history of IM have a three-fold increase in risk of HD [48], and 
Hodgkin's disease often have higher titers of antibody to EBV structural proteins 
even prior to disease presentation [49]. EBV DNA and gene products can be 
found in Reed-Stemberg cells [46，47] and monoclonal viral genome was 
subsequently localized to RS cells [50:. 
50% or more of H D c ases i n d eveloped c ountry, 1 00% i n d eveloping countries 
from S outh A merica w ere a ssociated with t he v irus. T he i nfected t umour c ells 
expressed a limited number of latent proteins, which are LMPl, LMP2, and 
EBNAl [44]. 
Nasopharyngeal Carcinoma (NPC) is a tumor 1 ocatedinthepost-nasal space. 
The disease shows marked geographical restriction, and is particularly in ethnic 
Chinese populations. Thus it is the third most common form of tumor in Hong 
Kong, occurring with an incidence of approximately 50 cases per 100,000 
individuals per year [51]. Although rare in other parts of the world, small areas of 
high prevalence are found in Aslaska, Iceland, and in parts of central and North 
Africa [52]. 
NPC arises from squamous epithelial cells and is classified according to the degree 
of differentiation shown by the tumor cells. At least, 70 % of total cases worldwide 
are undifferentiated; others are either non-keratinizing or squamous cell 
carcinomas. Tumors of the undifferentiated and non-keratinizing forms usually 
contain a large infiltrate of non-malignant T cells. Early metastasis sites of the 
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tumour are cervical lymph nodes, and node enlargement is the presenting symptom 
in around one third of cases. Other cases present with nasal obstruction, bleeding, 
discharge, deafness, tinnitus or cranial nerve palsy. Diagnosis is made on 
histological examination, and the treatment of the choice i s radiotherapy, which 
gives a five-year survival 60% in early stage disease [53, 54 . 
What role EBV plays exactly in the etiology of NPC is not known. A link was 
first suggested o n t h e b a s i s of sero-epidemiologic studies showing that antiviral 
antibody titers are elevated in NPC patients [23，55]. The anti-EBV antibody 
profile is altered when tumors are surgically removed [56]. Later, the EBV DNA 
was confirmed in the malignant epithelial cells [57]. Studies show that nearly 
100% of anaplastic or poorly differentiated NPC contain EBV genomes and 
express EBV proteins; the form of virus DNA in the tumors is monoclonal and 
every cell carries the virus, implying that the virus had infected the original tumor 
cell. After surgical resection of NPC tumor, EBV DNA in plasma probably 
released from dying tumour cells decreasing significantly in very short time, the 
median half-life is 139 minutes, and after a median follow-up 6.7 days, the EBV 
DNA is undectectable [58�. 
The malignant epithelial cells of NPC show a restricted pattern of latent EBV gene 
expression, that is, the virus infected tumor cells only express LMPl, LMP2, and 
EBNAl (Table 2). Measurement of EBV-specific antibodies, especially antibody 
titers to VGA and EA, has been used in screening patients for early diagnosis of 
NPC in Southern China. An increase in EBV-specific antibody titers after therapy 
for NPC is associated with a poor prognosis, whereas a declining or constant level 
of antibody is associated with a better prognosis [59, 60]. 
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Gastric carcinoma: Gastric carcinoma is one of the most common tumours in the 
world, and the worldwide occurrence of EBV-positive gastric carcinoma is 
estimated at more than 50,000 cases/year [61]. EBV is associated with 4% to 18% 
of all gastric cancinomas depending on different geographical region [62-66]. In 
Chinese, 4.5% of the tumor is associated with the vims [61:. 
Only EBNAl is consistently expressed in these tumors, and in some cases, 
LMP2A is also expressed. This expression pattern is most similar to that of 
Burkitt's lymphoma [67，68: 
Other cancers: EBV is also associated with a number of other rarer cancers, such 
as nasal T-cell/natural-killer lymphomas, lymphomatoid granulomtosis, 
angioimmunoblastic lymphadenopathy, and central nervous system lymphomas in 
immunocompromised patients [69, 70]. McClain [71] also found an association of 
EBV with leiomyosarcomas and leiomyomas in children with AIDS. 
Different EBV disease states exhibit different range of latency, the relationship 
between latency type and disease is listed in Table 3. 
Table 3 EBV-related disease and latency type 
EBV-Related Disease Latency Type 
Burkitt lymphoma I 
Gastric carcinoma I 
Nasal natural killer lymphoma H 
Hodgkin's lymphoma n 
Nasopharyngeal carcinoma H 
T-cell lymphoma 11 
Infectious mononucleosis HI 
m rimi—imii n ii • (i]i in --n-n 1—r rn-t .-： 
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Host-transplant lymphoproliferative disorders/lymphoblastic III 
lymphoma 
1.3 T Cell-Mediated Immune Response to EBV 
1.3.1 The Pathway of Cell-Mediated Immune Response in Viral Infection 
Cell-mediated immune responses play a pivotal role on virus infection. The cells 
are T lymphocytes including CD4+ and CD8+ phenotype. Here, we only focus on 
CD8+ T cells, which we also call cytotoxic T lymphocytes (CTLs). 
The CTL response is mediated against antigen prefered through HLA class I 
pathway. The prerequisite for CTL responses are that the target proteins must be 
degraded into small peptides (epitopes), the suitable length is 8-10 residues, 
presented by class I human leucocyte antigens (HLA) [72]. For a peptide to be 
immunogenic, it must satisfy the following conditions (Figure 1-3). First, the 
protein must be cleaved into relevant peptides in the cytosol, most probably by the 
proteosome system [73-76]. Second, relevant peptides must be delivered into the 
endoplasmic reticulum via the TAP1/TAP2 transporter complex) [77]. Third, in 
endoplasmic reticulum, the peptides must be bound by nascent HLA molecules to 
form peptide/HLA complexes for presentation on the cell membrane [78, 79]. 
HLA class I molecule select peptides based on the complementary structure of the 
peptide and the polymorphic pockets within the peptide-binding groove [80，81]. 
At certain sites within 8-12 amino acid peptides bound to paticular HLA class I 
molecules, one or more amino acids are found to be nearly invariant. These amino 
acids are called the dominant anchor residues because they ‘‘anchor” the peptide 
into the pocket of groove, other positions at sometimes also enriched for specific 
amino acids and are thus defined as auxiliary anchor residues [76, 82]. Fourth, the 
peptide/HLA complex need to be complementary to CTL receptors, in the host 
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repertoire, the affinity of TCR binding and the abundance of the complex at the 
target c ell s urfaces are r egarded as the factors d eterming the o verall size of the 
response individual [83]. 
A central feature of CTLs responses are the presence of a hierarchy of viral 
epitopes [83]. That is, many potential epitopes may be displayed to the immune 
system, but the T cell response usually focuses on only a few that elicit strong 
immune response. Others provoking a less T cell response are regarded as 
subdominant epitopes. The phenomenon is called immunodominance [83 • 
Figure 1-3 The immune response model of CTLs 
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1.3.2 Cell-Mediated Immune Response to EBV 
The history of cell-mediated work in the EBV began with the observation that 
most activated T cells in acute M patients are CD8+, and these T cells are also 
specific to the virus [86, 87]. Clearer evidence come from that T cell donors can 
block the outgrowth of autologous EBV-infected B cells in vivo [84, 85] [88]. This 
regression of EBV-transformed LCLs can be reversed by simply adding 
immunosuppressive drugs which block the reactivator of virus-specific CTLs [89:. 
Further firm proof come from clinical trial. Rooney [90] transferred in vitro-
reactivated autologous CTLs into PTLD patients and proved that there did control 
the EBV lymphoproliferative disease. Also O'Reilly [91] infused unirradiated 
donor leukocytes into patients with EBV lymphoproliferative disease after bone 
marrow transplantation, leading to the resolution of t he lymphomas. O n e year 
after treatment with EBV-specific cytotoxic T cells, two of three patients with 
lymphoproliferative disease had complete regression [92, 93]; and such patients 
had reduced levels of EBV DNA in their blood [94]. Further studies showed EBV 
infected cells can be eliminated by specific CTL [95, 96]. So CTLs play key role 
in controlling both the primary and persistent phases of EBV infection. 
Most of primary response models are from infectious mononucleosis (IM), whose 
classic feature is a vigorous lymphocytosis [29]. The expanded lymphocytes are 
mainly CD8+ cells [97，98]. Most of the highly amplified CD8+ T cells are EBV-
specific and are directed against the invading pathogen [99，100]. The CTLs 
respond to both lytic and latent antigens, but the proportion of CTLs to the two 
kinds of antigen is different. Basing on HLA-B8-restricted epitopes, BZLFl from 
a lytic antigen, and a latent antigen, EBNA3A，from a lytic antigen, lytic epitope 
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specific T cells composed around 44% of the total CD8+ T cells while 1.2-2.2% 
CD8+ T cells respond to the latent epitope [99]. Other studies also showed that in 
primary infections of IM, CTLs respond directly to EBV lytic proteins. After the 
resolution of acute infection, lytic epitope-specific CD8+ T cell numbers rapidly 
declined, but most remain detectable throughout carrier state [101, 102]. Some 
researchers found that the phenotype of the cells in the primary infection is mainly 
CD45 RA-R0+CCR7-, typical of activated effector cells [103, 104: • 
After the acute infection is brought under control, the viral load diminishes and the 
great majority of primary effectors die by apoptosis [105, 106]. However, some 
virus-specific CD8+ T cells survive and enter the memory pool, they persist there 
and can presumably be reactivated by challenge from any second exogenous 
infection or from a re-activated of its exsiting endogenous infection. 
In vitro, EBV-specific CTLs in the blood of healthy virus carriers can be 
reactivated by stimulation with the autologous LCL [107-109], indicating that T 
cell memory responses in vivo [103]. But there is a marked difference in the T cell 
populations between the primary and persistent infection, the primary response is 
dominated by lytic epitope specificities while latent specifities are less abundant. 
The lytic versus latent effectors composition of the persistent stage is vice versa. 
Cells phenotypes are also memory CTL to latent epitopes remain CD45RA-RO+ 
with a greater tendency to acquire CCR7, which is the memory marker [103，110]， 
memory CTLs to lytic epitopes are generally CCR7- with a partial reservior to a 
CD4 RA+RO- phenotype. 
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1.3.3 The Feature of CTLs Response to EBV 
There are three known features of CTLs response to EBV. 
First, the composition of the response depends on the course of the infection. As 
described above, CTLs skew to respond to lytic epitope in primary infection, while 
in persistent infection, the response is equally split to both lytic and latent epitopes. 
The switch of the response reflect the levels of lytic antigen decreasing [111], and 
latent antigens increasing in latent infection [103'. 
Epitope choice is always limited in individuals [112], with a small number of 
epitopes being immunodominant [112]. The classic example is HLA B8-positive 
Caucasions who consistently show dominant responses to an epitope, 
FLRGRAYGL, which derived from EBNA3A protein [113] and an epitope, 
RAKFKQLL from the BZLFl protein [114]. On the other hand, HLA B35-
positive individuals tends to recognize another EBNA3 epitope, YPLHEQHGM 
[115]. Despite the wide background of HLA, most immunodominant epitopes 
derive from EBNA3 proteins, for instance, the HLA-All-restricted response to 
EBNA3B [116], the HLA-B8-restricted response to EBNA3B [117], the HLA-B27 
restricted response to EBNA3C [118], and the HLA-B44-restricted response to 
EBNA3A [119], To date, more than 70 epitopes have been identified by epitope 
mapping [96]. Approximately 50% of these epitopes are derived from EBNA3 
family [120]. Thus the second feature of EBV latent antigen specific CTLs is that 
the dominant reactivities are frequently directed against the EBNA3 family 
epitopes, sometimes accompanied by sub-dominant reactivities against to one or 
more other latent antigens, EBNA2, EBNA-LP, LMPl and LMP2 [112，121-126]. 
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The third feature of CTLs response is that EBNA-1 specific CTLs do not recognise 
to virus-infected cells expressing EBNAl protein in vitro [127][128]. It has been 
proposed that this resistance to CTL mediated recognition is mediated by a unique 
glycine-alanine repeat (GAr) domain amino acid sequence in EBNAl protein. The 
GAr interferes with antigen processing at its level of proteasomal breakdown 
129]. Further studies show inserting GAr domain into the EBNA3B sequence 
greatly reduces the efficiency with which the epitope is presented for CTL 
recognition [130], so that the effect is referable to other sequences but only if they 
are linked to the Gar domains. 
1.4 CTLs to EBV Relevant Malignancies—Applications and Challenges 
Although the causative role of EBV in many associated malignancies is not clear, 
strong T-cell memory responses to EBV in the blood of healthy vims carriers [88， 
131] provide a source of effectors for potential CTL therapy against the vims-
infected tumor cells. The preliminary studies focused on adoptive T cell 
immunotherapy. The key step includes cocultivation of PBMCs with an 
autologous EBV-infected lymphoblastoid cell line to favor expansion of vims 
latent antigen specific CTLs [132]. In EBV lymphoproliferative disease of 
haematopoietic stem cell transplantation (SCT) patients, Papadopoulos infused 
donor P BMCs i nto SCTp atients f or t reatment. T hey found t hat i nfusion c ould 
induce complete regression of EBV-LPD in SCT recipients but with a high risk of 
graft-versus-host disease (GVHD) [133]. Encouraged by the success of the 
experiment, autologous EBV-specific CTLs first expanded in vitro have been used 
in patients with EBV related lymphoproliferative disorder [134-137]. In 2002, 
researchers infused allogenic partially HLA-matched EBV specific CTL preparator 
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into the refractory EBV associated lymphoma [138], and in EBV-positive 
Hodgkin's disease patients with relapses [94, 139]. After adoptive transfer, two of 
three patients showed diminution of symptoms, and all of three had reduced levels 
of EBV DNA in their blood [94，139]. Autologous Epstein-Barr vims-specific 
cytotoxic T cells have also been used to NPC, and show encouraging results in the 
patient [140]. In preparator of CTLs from EBV LCL stimulation, LCL-responsive 
CD8+ cells constitute l l%-22% of the total cell used for infusion [141:. 
These preliminary clinical trials only got incidental improvement such as 
resolution of some symptoms, reduction of high virus load, stabilization of the 
disease. Unfortunately, all of these patients failed to recover from the advanced 
stages. 
One major limitation of the method stems from the phenomenon 
immunodominance. Since there is marked skewing of the latent antigen-specific 
responses towards a particular subset of latent proteins, namely EBNA3A, 3B, 3C, 
such polyclonal CTLs from the LCLs stimulation are unlikely to be as effective 
against to NPC or HD, because the tumor cells do not express these proteins. 
Although LCLs can present theLMPl, LMP2 epitopes and thus stimulate LMP 
specific CTLs response, The immunodominant response to EBNA3 family 
epitopes may mask and eventually reduce the presentation o f LMP 1 and LMP2 
specific CTLs in such polyclonal preparators [122]. Furthermore, the in vitro-
reactivated method is complicated and lasting logistically. It is very difficult to 
use when treating a large number of patients, especially in the case of NPC, which 
is highly endemic in South-East Asia. 
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Against this background, epitope-based therapy, n amely u sing “ f ormulations of 
synthetic peptides that mimic immunodominant epitopes known to be recognized 
by the natural virus-induced CTL response" [112], are thought to be an alternative 
way to overcome this because they can selectively expand the particular antigen-
specific responses we need in specific diseases. Researchers therefore now focus 
on the selective reactivation of memory CTLs in specific malignancies using 
defined peptides. 
Using a synthetic peptide (IVT) as an in vitro stimulations, Reali [142] 
demonstrated that re-activated IVT-specific clones are as efficient as those 
produced by conventional LCL stimulations, which give great impetus to efforts at 
designing a peptide-based vaccine against malignancies. 
A successful epitope-based therapy would require many conditions to be reliable. 
One is that the tumor is immunogenic; another is that intact cell-mediated 
immunity exists in the host. F or instance, NPC tumor c ells only present at the 
most with viral proteins, EBNAl, LMPl，LMP2 [143, 144], EBNAl is unlikely to 
be an effective target for a CTL-based therapy because it is protected from 
processing and presentation to HLA class-I-restricted T cells. LMPl protein is 
poor immunogenic and seldom elicits CTL response [145], the better immunogenic 
protein is LMP2 [112, 121, 122]. The protein has not been fromally proved to be 
expressed in NPC biopsies but LMP2A and 2B mRNA transcripts are detectable in 
NPC [143]. Moreover, NPC patients have uniquely high levels of serum 
antibodies to LMP2 [146] suggesting that the tumor cells are its source of the 
antigenic stimulations. 
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Based on preliminary studies, NPC tumor appears to have an intact cell-mediated 
immunity pathway. The tumor is capable of processing endogenously expressed 
EBV Ags. Also EBV-specific CTLs cultured from NPC tumor biopsies possessed 
a detectable response to LMP2 and these effectors recognised LMP2-expressing 
NPC tumour cells in vitro [147:. 
The EBV-specific CTL response in NPC is weak [148，149], but experiments 
using autologous dendritic cells pulsed with LMP-derived peptide suggests that the 
problem may be solved by boosting [150]. Indeed, a recent clinical trial shows 
that 9 of 16 NPC patients have responses boosted after immunization with LMP2 
epitope-pulsed dentritic cells, and two of these 9 responders showed a reduction of 
the tumor size [151]. 
Epitope responses are highly HLA-allele specific, such that specific epitope choice 
is related to HLA polymorphisms, coping with its effects of such polymorphisms 
may be the real challenge for therapeutic vaccine design [112]. 
1.5 HLA Polymorphisms and Strategy of Epitope-Based CTLs Therapy 
HLA class I molecules are cell-surface glycoprotein encoded by the MHC cluster 
genes. The molecules comprise heavy chains with a l , a2, a3 domains, and a light 
chain, p2 microglobulin. The class I HLA can bind epitopes through peptide-
binding motifs which are formed by a l and al chain. Since the peptide-binding 
motif in the molecule contains position-specific amino acids which interact with 
the epitope, epitope responses are highly allele specific or sub-allele-specific 
[112]. 
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One important feature of HLA class I molecules is polymorphisms. That is, within 
each molecule, and even at one 1 ocus, a 1 arge number ofvariants (polymorphic 
forms or alleles) exist in the population as a whole. To date, more than 100 class I 
alleles are already known [152]. Different human population have their own 
distinct patterns of HLA polymorphisms. For instance, in Caucasian, some HLA 
alleles, such as A2, A3, B7, B8, and B44 [153], are relatively common, while in 
Southern Chinese common alleles (table 4) are A2, A l l , A24, and B40 [154, 155:. 
To add complexity, some alleles have a lot of variants; for example, HLA-A2 has 
at least 17 variants worldwide. The A2 allele is almost equally prevalent in 
Caucasians and in Southern Chinese, but the subtype distribution is significantly 
different [156-158] (Table 5). We will discuss this in the next chapter. 
The degree of HLA polymorphism in different population presents the biggest 
challenge to the design of an EBV vaccine because constituent epitopes should 
cover most common HLA alleles in the patient population. Base on the defined 
epitopes, "Using appropriate mixtures of synthetic epitope peptides or by 
constructing vectors to express polypeptides in which the relevant epitope 
sequences are linearly joined together" [112] may overcome the HLA diversity. 
One such "cocktail" would cover about 85% of the Caucasian population [112, 
120]. It is also possible to promote the efficacy due to a lack or loss of antigen 
expression [159], and thus increase potency, and break tolerance [160-162]. 
Indeed, a polyepitope vector can express all the component epitopes in the cells, 
and each component can elicit specific CTLs response in the lab [163, 164]. The 
specific CTL response induced by such a polyepitope was capable of depleting 
tumor cells in murine models [62, 164]. 
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More than 70 distinct EBV-coded CTL epitopes have been identified [112，116, 
117，119，121，122，165-168]. It would be very difficult to integrate all these 
peptides into one polyepitope, because that may “present formulation difficulties 
and potentially pose significant problems with regulatory authorities" [167]. So 
the ideal polyepitope should represent the minimal estimate of epitopes required to 
cover the maximum number of common HLA alleles. This aim is made so reach 
at easier by the concept of supertype epitopes which are capable of binding 
multiple related HLA types. 
HLA allelic molecules now are classified into supertypes characterized by largely 
overlapping peptide-binding repertoires reflecting a consensus structure of the 
main B- and F- pocket of their peptide-binding grooves. Epitopes presented by 
supertype family members were defined as supertype epitopes [169，170]. The 
concept was first exemplified by the fact that HLA-A3 and A11 recognized very 
similar motifs and they have significant overlap in their peptide-binding repertoires 
[171]; the study also showed that A31，A33 and A6801 have the same overlapping 
area. These alleles with themselves were defined as the A3 supertype. Beside the 
A3 family, three other supertypes families [170] were found in the ealy study. That 
is the HLA-B7 [172, 173], HLA-A2 [174，175] and HLA-B44 supertypes [176]. 
Later, of five new supertypes, Al , A24, B27, B58, and B62 were also added [177；. 
Supertype epitopes are the most ideal candidates for polyepitope vaccine 
constructs because each supertype of the HLA class I family can cover about 35-
45% of the general population [169], and “cocktail” of three supertypes can cover 
83-89% of population in Caucasians [170]. 
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1.6 The Effect of HLA Polymorphism on EBV-Specific CTL Epitope Choice 
in Southern Chinese 
The relationship between epitope choice and specific allele is one of the challenges 
for the vaccine designation because T cells responses are correlate with the affinity 
of binding to the relevant HLA molecules [80, 81], or the stability of the 
corresponding HLA-peptide complex [83]. In southern Chinese, the most 
significant alleles are A l l and A2 [154] (Table 4)，both seen in -50% of the total 
population. 
The situation with respect to HLA-Al 1 is very interesting because of the 
controversial suggesting that high HLA-Al 1 frequencies may have influenced the 
evolution of virus in Chinese population. Screening of polyclonal CTL cultures 
for peptide-specific reactivities in HLA-Al 1-positive Caucasians has shown focus 
on two EBNA3B epitopes, IVT and AVF. In the Caucasian population, A l l 
frequency is around 10% [169]. The IVT epitope response accounts for as much 
as 80% of the EBV-specific CTL clones isolated from donors, and the AVF-
response accounts for most of its rest [178]. Thus IVT is regarded as 
immunodominant and AVF is the subimmunodominant epitope. Another A l l -
restricted epitope, SSCS from LMP2, elicits much weaker responses than IVT or 
AVF [116，123, 179]. The interesting thing is that both IVT and AVF sequences 
are highly conserved in the type 1 isolates of Caucasian and Africa origin where 
HLA-Al 1 frequenies are quite low (3%). But in coastal Papua New Guinea 
(PNG), HLA-Al 1 allele frequency is very high (-50%); and these epitopes are 
often mutated in PNG-derived EBV strains. The mutation frequently happens at 
the A11 anchor residue 424 (position 9 of the IVT epitope) which changes a lysine 
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to threonine. The variant peptide does not bind to HLA-Al 1 molecules and thus 
deemed not recognized by the allele restricted CTLs [180]. The same phenomenon 
exists with AVF; then is frequent mutated and the mutated epitopes also are 
deemed to be non-antigenic [181], although this was not investigated in detail. In 
a larger but again highly A l l positive population ----Southern Chinese, the 
changes are seen at important position 2 or 9 of the IVT epitope and positions 1 
and /or 2 of the AVF epitope [182]. Comparing the frequency of mutation in the 
three populations, the authors hypothesized that viruses with IVT/AVF variants 
sequences enjoy a selective advantage in highly All-positive populations. 
Burrows et al [180] and Khanna et al [183] objected to this hypothesis. 
Their evidence was that the epitope-loss variants occur not only in coastal 
PNG but also 
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Table 4 HLA Frequencies in Southern Chinese 
HLA type Frequeny (%) 
A2 53.27 











in highland PNG, which HLA-Al 1 frequency is very low. They also sequenced 7 
regions across the EBNA3 genes and LMP2 gene, which contained 9 epitopes 
restricted through HLA A29，A24, A23, B7, B8, B35, B44 and B27. Their results 
suggested that the frequency of mutation within the epitopes was not significantly 
higher than that observed in the flanking regions, and that epitope mutation did not 
correlate with the specific alleles within the population. They suggested that the 
reported A l l epitope mutations were purely a result of random drift and/or a 
chance founder effect in PNG and Southeast Asian populations. 
In addition, the A11-restricted response in Chinese is of particular interest because 
there is some evidence to suggest that this HLA allele is associated with a reduced 
risk of developing NPC [184, 185]. 
Special interest has been bestowed upon HLA-A2 as a restriction element because 
it is one of the commonest but also the most heterogeneous of its class I alleles 
with at least 17 different subtypes (designed as A0201-A0217) [186]. For 
instance, HLA-A201 -specific consensus-binding motif is 9 amino acids in length 
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with dominant anchors of Leu at position 2 and Val or Leu at position 9 [82]. The 
other subtypes differ by 1-5 amino acid residue substitution with HLA-A201 at the 
floor of the binding groove [81，187，188]. Same A2 subtypes have been 
demonstrated to be functionally distinct in their ability to bind and present peptides 
189]. H owever, t he p ossibility of A 2-supertype-restricted e pitope p eptides i s 
very appealing from a vaccine perspective. 
Most of Caucasians are HLA-A201; non-A201 subtypes are relatively infrequent 
(�50/0 of A2-positive individuals). In Singapore Chinese (the distribution is 
probably quite similar with Hong Kong people), one Study showed that, in 66 
Singapore Chinese, A2 occupies about 53% in the population, A201 occupies 
about -20%, while HLA -207 are distinctly most common (-45%) in Southern 
Chinese. Other A2 subtypes also occupy important proportion in the population 
such as A203 [157，158]. Another study showed, in 85 Singapore Chinese, A2 
occupies �5 7 % in the population, the distribution of A201 occupies -20%, A203 
occupies -12%, and A206 occupies -25% [156]. The different sample size of two 
studies may be the reason of different A2 subtype positive frequencies, but both 
studies proved that the distribution of A2 subtypes in Southern Chinese is much 
wider than that in Caucasians. 
Wider HLA subtype distribution may influence epitope choice. This may due to 
the minor variation of HLA allele subtype structure. The amino acid difference 
may result in either remarkably similar [174，190，191] or totally different epitope 
choices [118, 192]. In melanoma studies, A2 restricted immunodominant 
epitopes, MT27-35, which come from Melan A/MART-1, can be recognized by 
several subtypes, the alleles can be divided into three groups according to the 
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ability of presenting the peptide: A201, 204，205 have the same capacity to present 
the epitope; A202, 206，209，6901 are less efficient and A207, 6801，6802 are 
unable to present the epitope [193]. A similar phenomenon appeared in the HLA-
B44 family. In HLA B44-positive EBV carriers, B4405- CTLs consistently 
displayed a very strong response to one epitope, EENLLDFVRF, while B4402, 
B4403 healthy vims carriers showed low to undetectable responses to the peptide 
122, 194]. Whether HLA-A2 subtypes influence EBV epitope choice in Southern 
Chinese is not known. 
Most of A201 restricted EBV epitopes were defined in Caucasians, and whether 
the well known A201 epitopes can be immunogenic in individuals with common 
Chinese subtypes like A203, A206 or A207 is not known. Some A2 family 
restricted epitopes were defined in Chinese donors, such as the EBNAl epitope, 
VLK, and an EBNA-LP epitope, SLR, from an A203 positive Chinese donor and a 
LMP2 epitope, LTAG, from an A206 positive Chinese donor. These were rare 
clones and how frequently such epitopes are immunogenic in Chinese populations 
is not known, nor if they are only immunogenic in A203 or A206-positive donors. 
The A2 supertype was defined based on similar peptide binding motifs in multiple 
different A2 subtypes [174, 175, 195]. The supertype minimally includes A201, 
A202, A203, A204, A205, A206, and A207 subtype HLA molecules [176，195]. 
In EBV studies, one A2 epitope, YLL，which is from the LMPl protein, is 
recognizable in the context of many A2 subtypes, A201, A202，A203, A204, 
A206, A6802, and A6901 suggesting that they are one supertypes family [145]. 
Another epitope, CLG from LMP2, can also be presented by A206, A207 and 
A209 [101]. However, these studies all looked at the capacity of A201-restricted 
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epitope-specific clones, they did not add the question whether these epitopes are 
activated immunogenic in vivo in individuals with their particular HLA-A2 
subtype alleles. 
Table 5 HLA-A2 subtype distribution in different populations 
HLA A2 Subtype Caucasian (%) Singapore Chinese Singapore Chinese 
(%)[158] (%)[156] 
“ A0201 ^ ~ 
A0202 — — — 
A0203 _ 23 12.8 
A0204 _ — 
A0205 _ _ 6.7 
A0206 1.6 8 24.8 
0207 45 
In total, many determinants but especially HLA polymorphism influence CTLs 
epitope choice in specific population. The overall patterns [119, 122, 194，196, 
197] seen in Caucasians may be different from those in other populations such as 
southern Chinese. Knowing the pattern of epitope choices in this population is the 
prerequisite for epitope-based CTLs immunotherapy, especially in NPC in the 
future. 
1.7 ELISPOT Assay — Detection of CTLs Response 
The ELISPOT Assay was originally described by Czerkinsky C as a method for 
the detection of single cytokine-secreting cells [198]. Herr W modified it for easy 
use [199]. The acronym ELISPOT is an abbreviation of Enzyme Linked Immuno-
Spot Assay. The array uses two high-affinity cytokine-specific antibodies to detect 
lymphokine secretion by individual cells following antigen stimulation [200]. The 
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number of spots increases proportionately with the frequency of the antigen-
specific immune cells in the rest population [201, 202]. In this assay, secreted 
lymphokines from antigen-stimulated PBMCs are antibody-bound to a solid 
support, usually a nitrocellulose plate. Basing on a colorimetric reaction, the 
captured secreted cytokines directly show their color at the site of secreting cells, 
so the spot acts to “footprint” cells, the Spots are permanent and can be 
quantitated. 
Currently, the Elispot assay was used as an alternative way of investigating CTL 
activity [199，201, 203]. It has been widely used in monitoring immune responses 
in patients undergoing immunotherapy [204，205] and in the assessment of vaccine 
efficacy [206-208], for example, in phase I/II HIV vaccine trials [209]. The 
quality of the ELISPOT assay depends on many factors, background effects, levels 
of the cytokine produced by individual cells, interactions between the plated cells, 
effectors/target cell ratio, and time of incubation with the peptides were all 
important for the number and appearance (intensity and size) of spots [202, 210, 
211]. 
The process of Elispot assay is outlined in the Figure 1-4. The wells of the 
ELISPOT plate are coated with antibody (immunoglobulin; Ig), this antibody is 
specific for the assayed cytokine. The Ig binds to the base of the ELISPOT plate to 
show the site of cytokine secreted. After the activated T cells are transferred to the 
ELISPOT plate, cytokines are released and captured by coated specific antibody 
(a, b, c，d), After the T cells and any excess cytokines are washed off, a second 
antibody specific for the cytokine is added (e, f); this antibody carries an enzyme 
that is capable of converting a substrate into an insoluble coloured product. After a 
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period of incubation, the plates are washed, and the enzyme substrate is added (g， 
h). The substrate is converted into the insoluble product, forming coloured spots 
(i), which locate the cytokine searching cells (j). 
The Elispot assay therefore detects T cell responses at the single cell level. The 
sensitivity of the ELISPOT assay was found to be 1/100,000 cells [204，212，213：. 
The assay is relatively simple, and only needs 48 hours' culture in vitro. 
Furthermore, for CTL responses, the results of the assay have good correlation 
with the chromium-release assay [214], however, the sensitivity is higher than 
5iCr-release assay [215]. The frequencies of T cells in the ELISPOT assay were 
also proportional to CTL precursor frequencies generated by the limiting dilution 
assay (LDA) [216，217] but with several fold higher (30-100 times) indicating the 
problems inherit in LDA. Studies with EBV epitopes showed that the frequencies 
of Tetramer staining assay (TSA) were 4.4 fold higher than Elispot IFN-T assay, 
but the results of Elispot assay were 5.3 fold higher than LDA [218]. The reason is 
maybe that LDA detects only CTL precursors involved into proliferated by 
antigenic stimulation in vitro [219] while the TSA detects all epitope-specific cells 
irrespective of their responsiveness to stimulation. 
Different cytokines were used as the read-out in ELISPOT assay. IFN-Y is 
thought to reflect T cell's ability to eliminate vims-infected cells and was 
frequently used [220，221]. In addition, TNF-a, TNF-p, IL-1, IL-2, IL-4, IL-5, IL-
6, IL-10, and granulocyte-macrophaqge colony-stimulating factor (GM-CSF) are 
also often used according to the different phenotypes of T cells under study [217, 
222]. Other protocols also include either the use of PBMC or separated CD8+ T 
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cells as effector cells, and antigen-presenting cells included monocytes, dendritic 
cells or tumor cells [210，216，218:. 
Table 6 Three methods to detect T cell response 
Method Frequency of Dependent on mechanism Detect 
estimate 
LDA Lowest Ablitity to proliferate and Underestimate, bias 
kill target cells in vitro [223: 
ELISPOT Medium (5.5- In vitro stimulation with Just not required to be 
fold LDA) relevant peptide Ag functional [218] 
TSA Highest (4-fold Expression of specific Cells may not secrete 
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1.8 Aim of This Study 
EBV infects at least 95% adult population worldwide and is linked to a number of 
malignancies, of which the most important for South East Asian populations is 
nasopharyngeal carcinoma. There is significant interest in exploiting the HLA 
class I-restricted CD8+ T cell response to EBV target antigens as a means of 
developing immunotherapeutic approaches to NPC treatment. However HLA 
) 
polymorphism may have a profound influence on epitope choice and much basic 
information still needs to be gathered about the immunodominant EBV epitopes 
that are presented by HLA class I alleles that are common in Chinese populations 
CD8+ T cell responses restricted through HLA-Al 1, a very frequent allele in 
Southern Chinese [155], are particularly interesting to study because Chinese EBV 
strains are frequently variant in two epitopes, IVT and AVF from the latent cycle 
antigen EBNA3B, that induce immunodominant responses in All-positive 
Caucasian donors. 
It is important to know whether these variant epitope sequences are immunogenic 
or silent in Chinese donors in view of previous work arguing that A11-restricted 
immune pressure has selected for EBV strains carrying "epitope-loss" sequences in 
this region of EBNA3B. The present work therefore set out to screen peripheral 
blood mononuclear cells (PBMCs) of Chinese donors in Elispot assays of 
interferon-gamma release for evidence of reactivity to wild type IVT and AVF 
peptides (i.e. the concensus B95.8 Caucasian strain sequences) and to the IVT and 
AVF variant sequences reportedly present in Chinese EBV strains. A third A l l -
restricted epitope SSC，from the latent membrane protein LMP2, provides an 
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important control since this is a poorly immunogenic epitope that is conserved in 
all Caucasian and Chinese virus strains. 
Responses restricted through HLA-A2 are also interesting to study since previous 
work on Caucasian populations has concentrated on epitopes presented by the 
dominant A201 subtype; by contrast there are at least four A2 subtypes common in 
Chinese populations and the effect of sub-type polymorphism on EBV epitope 
choice is unknown. The present work therefore also set out to screen Chinese 
donors for evidence of reactivity to known A201-restricted epitopes from EBV 
latent cycle antigens (in particular from the latent membrane proteins LMPl and 
LMP2) and from lytic cycle antigens (in particular from BRLFl, BMLFl and 
BMRFl). 
Finally the present work extended the analysis of responses in Chinese donors to a 
number of other peptides, mainly derived from the LMP2 protein sequence, that 
have already been identified as epitopes restricted through particular HLA alleles 
from studies on Caucasian donors; the aim here was to determine whether such 
responses are also detectable in Chinese donors, especially where Chinese 
populations possess an HLA allele that is closely related to the originally reported 
Caucasian restriction element. 
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2 Chapter 2: Material and Methods: 
2.1 Peptides 
The work used more than 40 synthetic peptides which were composed of the 
"standard epitopes" and mutants. “Standard，，means sequence of epitope is from 
the sequence of B95.8, and is mutant means amino acid change at some positions 
using B95.8 as the template. These epitopes are grouped into three parts by HLA-
restriction: A l l , A2 and non-All, non-A2 restricted epitopes. All the peptides 
were provided kindly by Professor Alan B Rickinson (CRC institute for Cancer 
Studies, the University of Birmingham, Birmingham, UK). 
The A11 part includes AVF, IVT and their mutants. One LMP2 epitope, SSCS, is 
also included (as Table 7). We gave the following shorthand designation. The 
parental epitopes AVF and IVT are shown A and I respectively. For mutants, the 
letters and numbers in parentheses denote the resultant amino acid and the position 
of the residue substituted. For instance, an IVT epitope that has leucine substituted 
for valine at position 2 is designated I (L2). The corresponding epitope frequencies 
2 2 
in type 2 prototype virus are also displayed and are designated A and I for AVF 
and IVT respectively. Table 8 gives the A2 restricted epitopes (12 peptides), and 
Table 9 is the non-A2, non-Al 1 restricted epitopes (11 peptides). The first column 
gives the HLA allele restriction of the epitope. The second column gives the 
shorthand designation by which the epitopes would be referred throughout this 
text, and third column gives the full sequence of the epitope. The fouth column 
gives the protein where the epitope comes from, and fifth column locates the 
position of the epitopes within the protein. 
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Table 7 HLA-Al 1 Restricted EBNA3B Epitopes: AVF, IVT and Their 
Mutants 
Designation Amino acid Sequence Protein Ref. 
AVF (399-408) — 
Type 1 AVFwtl AVFDRKSDAK EBNA3B [116，123，179] 
Type 1 A (N4) AVFNRKSDAK 
variants 
Type 1 A (S1F2) SFDRKSDAK 
variants 
Type 1 A (P1L2) PJ^DRKSDAK 
variants 
Type 1 A (P1) PVFDRKSDAK 
variants 
Type 1 A(A2) AAFDRKSDAK 
variants 
Type 1 A (S1L2) SLFDRKSDAK 
variants 
Type 2 A (A^) wt2 SVFYRKPDIK 
IVT (416-424) 
Typel IVTwtl IVTDFSVIK EBNA3B[116, 123, 179] 
Type 1 I (N9) IVTDFSVIN 
variants 
Type 1 I (L5) IVTDLSVIK 
variants 
Type 1 I (L2) ILTDFSVIK 
variants 
Type 1 I (T9) IVTDFSVII9 
variants 
Type 1 I (R9) IVTDFSVIR 
variants 
Type 2 I (|2)wt2 IVTDLSilK 
SSCS (340-349) S S C S S C ^ K LMP2 [foi] Chinese version 
Wtl refers to the Caucasian B95.8 prototype 1 sequence; wt2 refers to the African 
Ag876 prototype 2 sequence. 
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Table 8 HLA-A2 Restricted Epitopes in This Study 
HLA Designation Amino Acid Protein Amino Ref. 
(restriction) Sequence Acid 
(residues) 
A*0201 CLG C L G G L L T M V L M K 4 2 6 - 4 3 4 [224] “ 
A*0201 CLGVl SLGGLCTMV LMP2 426-434 [224] Chinese version 
A*0201 CLGV2 SLGGLLTMA LMP2 426-434 [224] Taiwanese version 
A*0201 FLY FLYALALL LMP2 446-454 [225] 
A*0201 GLC GLCTLVAML BMLFl 280-288 [226] 
A*0201 LLW LLWTLVVL LMP2 329-337 [101] 
A*0201 TLD TLDYKPLSV BMRFl 208-216 [227] 
A*0201 YLL YLLEMLWRL LMPl 125-133 [145] 
A*0201 YLLVI YLLEILWRL LMPl 125-133 [145] Chinese version 
A*0201 YLLV2 YLEILWRL LMPl 125-133 [145] 
A*0201 YLLV3 YFLEILWRL LMPl 125-133 [145] 
A*0201 YLQ YLQQNWWTL LMPl 159-167 [145] 
A*0201 YVL YVLDHLIVV BRLFl 109-117 [227] 
A*0203 LLS LLSAWILTA LMP2 447-455 [147] 
A*0203 SLR SLREWLLRI EBNA-LP 284-292 [147] Chinese version 
A*0203 VLK VLKDAIKDL EBNAl 574-582 [228] Chinese version 
A*0206 LTAg LTAGFLIFL LMP2 453-461 [101] Chinese version 
Note: Chinese and Taiwanese version means the sequence of epitope are identified 
in Chinese and Taiwanese donors 
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Table 9 Epitopes Restricted by Other Series of HLA Alleles 
HLA Designation Sequence Protein Amino Ref. 
(restriction) Acid 
(residues) 
A * 2 3 0 1 P ^ PYLFWLAAI L M P 2 1 3 1 - 1 3 9 [229 ~ 
A*2402 TYG TYGPVFMCL LMP2 419-427 [101] 
A*2402 TYGSL TYGPVFMSL LMP2 419-427 [101] Chinese version 
A*25 VMS VMSNTLLSAW LMP2 442-451 [112] 
B*2704 RRRW RRRWRRLTV LMP2 236-244 [118] 
B*3801 YHL YHLIVDTDSR EBNA2 14-23 [230] Chinese version 
B*40011 lED lEDPPFNSL LMP2 200-208 [101] 
B*40011 lEDSI lEDPPFNSI LMP2 200-208 [101] Chinese version 
B*4601 VQP VQPPQLTLQV EBNA3A 617-625 Unpublished 
B*5801 VSF VSFIEFVGW EBNA3B 279-287 [147] Chinese version 
B*63 WTL WTLVVLLI LMP2 331-338 [101] 
Note 1: Unpublished data from A.B. Rickinson 
Note 2: Chinese version means the sequence of epitope are identified in Chinese 
donors 
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Peptides were diluted in 200ul of RPMI+Penicilin-streptomycin solution (sigma, 
P-0781) to make a concentration at 200ug/ml in a stock plate. Then further diluted 
to 20ug/ml, this plate (Sarstedt, Germany, 1090163) was preserved in —80 C 
freezer which was used in the experiments. 
2.2 PBMCs Preparations 
Buffy coats (�50ml) (from HK Red Across Blood Transfusion Service) were 
diluted 1:3 with Hanks balanced salt solution (HBSS) (Invitrogen corporation, 
14170-112). After stirring the diluent by gently pipetting (Drummond) the diluted 
blood was aliquoted into five/50ml falcon tubes above 15ml of Lymphoprep 
(Amersham Pharmacia Biotech AB, Sweden) and centrifuged (lEC GPS, thermo 
life sciences, HK) at 1600rpm for 30 minutes at room temperature into four 
layers—red blood cell layer, lymphoprep layer, PBMC layer and a plasma layer. 
Using a plastic pipette (Falcon, Beckton Dickinson company France), the PBMC 
layer was transferred into another two-falcon tube with 25ml HBSS and mixed 
well. The tubes were centrifuged again at 1300rpm for 10 minutes, supernatant 
was discarded and the cell pellet was re-suspended in 25ml of HBSS in each tube. 
The cell pellet was washed once by centrifugation at 950rpm for 5 minutes, and 
resuspended in 20ml HBSS. Following a third wash of above, the pellet was 
resuspended in 40ml 10% FBS strep media (RPMI). 
2.3 PBMC Counting and Cells Dilution 
The PBMC solution was mixed well by gentle pipetting. 0.5 ml solution was taken 
out and then diluted to 5 ml by HBSS. A drop of solution was placed in a cell 
count plate, (ISL Corp, BVSlOO), cell numbers were counted under the 
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microscope. Counting of each sample was performed for at least 3 times by two 
different people; the final cell concentration was decided by the average of the 
counting numbers (cell concentration is: Cell /ml= sum of counting numbers in 
large square/n x lO* x 10, n=times of counting). 
Base on the calculation of cell concentration, cells were diluted to 5xlO^/ml, 
2.5xl0^/ml, and 1.25xl0^/ml in three tubes respectively. Cells were counted again 
in each tube to confirm that the dilution concentration was consistent with the 
expected numbers. The remaining cells were resuspended in freezing median 
(10% Analytical Dimethyl sulfoxide (DMSO) (Fisher, D/4121/PB08), and 
preserved into 6 labeling vials in the -80 C freezer overnight, and then transferred 
into liquid nitrogen to preserve for further study. 
2.4 Elispot Assay 
Anti-IFN-T mAb 1-DlK (Mabtech company, 3420-2 kit) was diluted in PBS to a 
final concentration of 7ul/ml. Ninety-six well Elispot plates (Multiscreen 
immobolin-p filtration plates, Millipore, MAIPN4550) were c oated w ith 50ul of 
this solution and incubated for 3 hours at room temperature. The wells were 
washed six times with 200ul ofRPMI 1640 medium, and then blocked with 200ul 
filtered (0.2 urn) media (RPMI 1640 containing 10% fetal calf serum (FCS)) for 1 
hour at room temperature. After flicking off the blocking media, serial dilutions of 
PBMC was added into the corresponding wells to a final volume of lOOul. 
Prepared peptides (20ug/ml) were added to wells in lOul to give a final 
concentration of 2 ug/ml. Positive control wells received lOul Phytohaemoglutin 
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(PHA) (Img/ml) (ICN, 151884), while the negative controls had only PBMCs. 
The plates were incubated overnight at 37 C in 5%C02. 
On the next day, the ELISPOT plates were washed free of cells six times with 
PBS-TWEEN (prepared by dissolving 50 tablets of PBS in 5 liters of water with 
2.5ml of TWEEN). After the last wash, 50ul of the biotinylated anti-IFN-T mAb 
7-B6-1 (MABTECH, 3420-2 kit) (0.5ul/ml) were added to each well, and then the 
plates were incubated for 3 hours at room temperature. The plates were then 
washed six times with PBS-TWEEN. Fifty ul of streptavidin-alkaline phosphatase 
(0.5ul/ml) (MABTECH) was added to each well and incubated for 2-hour at room 
temperature. The solution was then tipped off and the plates were washed with 
PBS-TWEEN. After six washings, lOOul of freshly prepared solution of 
BCIP/NBT (alkaline phosphate conjugate substrate kit, Bio-rad laboratories, 
1706432) was added in each well and incubated at room temperature until spots 
appeared in the wells. Using the PHA-stimulated wells as a strongly positive 
indicator of spot development. The plates were then washed thoroughly with 
running tap water and tipped on a piece of dry paper and finally air-dried. 
2.5 Counting the Spots 
Under the microscope (Leicagz6), only well-defined spots consisting a dark center 
surrounded by a lighter “halo” were counted, each counting number were input in 
the file of an EXCEL spread sheet. 
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2.6 Spots Forming Cells (SFC/10^) and Positive Standard 
Results are expressed at the number of spots in the peptide wells minus the mean 
number of spots in corresponding negative control wells. For only one peptide-
induced response, the number of spots in the wells should be consistent with the 
input cell number. Frequencies were expressed as the number of SFC/10^ PBMCs. 
After backgrounds had been subtracted, positive response were defined when the 
frequency/106 was higher than the mean frequency of blank plus 2 times standard 
deviation (SD)，namely 95% CI of blank frequency. 
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3 Chapter 3: Results 
3.1 Validation of ELISPOT assay methodology 
Defined epitopes in different HLA populations were selected to perform ELISPOT 
assay. Peptides were set by three serial diluent wells, after assay, the spots were 
calculated under microscope by eyes. 
There were two counting times in this assay, PBMC counting and Elispot spots 
counting. Since they are all performed by eye, it is very important to confirm if the 
countings were relatively accurate or consistent. 
We counted the PBMC at least three times on first separation, base on this 
counting, we extracted number of cells out to make designed cells concentration, 
then this was the theoretically number of cells (appendix 1: cell number in 
column). After diluting the cells, we counted the cell numbers again (appendix 1: 
final cell number in column). Most of the frequencies were based on the second 
counting of PBMCs. But in one part (Hkcont208-Hkcont267), we didn't have 
second countings; we had to use the first counting of PBMCs as the calculation of 
frequencies. Then we need to know if the two times of counting are consistent. 
We tested this question in Hkcont 268-2170. Statistic showed there was no 
difference between two times of countings (paired T test, a>0.05, data not shown) 
which warrant the consistence of the data. 
Counting spots was another key factor to calculate frequencies. Many studies used 
the automated ELISPOT reader with relevant software [231], but regulating 
standard is also complicated because of individual different samples. 
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There was no automatic counting system in our lab, we counted the spots under 
microscope by eyes. To ensure the counting of the spots consistently, we obeyed 
the conventional definition of the spots, that is, only large spots with fuzzy borders 
were scored as SFCs [216]. 
First, we need to know if the cells responded. Namely, we need to establish 
positive control. Many substances can be positive controls, such as PHA and 
ionophores such as PMA and ionomycin [213], these substances provide a yes/no 
answer to the assay. PHA is not a standard reagent; different manufacturers may 
have different spot standardization. The average number o f P H A s p o t s per well 
observed is about 5000 SFC/10^ PBMC [232]. But one study showed PHA >50 
spots/2.5x10^ were positive [233]. 
In our assay, we used PHA as a positive control The definition of “good’，PHA 
was spots numbers are at least 100 in each well and the spots are very clear to see 
by eye or under microscope in three wells. Since PHA is a non-specific strong 
stimulation reagent to T lymphocytes, all the counting of PHA wells should be 
always much bigger than peptide responding wells. This is always one of reliable 
standard that if the response happened. The responding spots should be always 
consistent with the PHA spots' shape, size when meeting the “difficult” spots. 
Then we went to check negative control. Negative controls ensure to screen the 
spots of IFN-Y are only from CD8+ T cells secreting. There are several kinds of 
negative controls, such as incubated cells alone, or with the control peptide without 
cells. Studies in EBV epitopes have shown there is no difference between them 
[141]. In the study, we used the blank wells, that is, we only had cells in the wells 
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and did not add anything. So in normal c ondition, the spots in the blank wells 
should be very rare and keep the double relationship among the corresponding cell 
numbers in the wells. 
Thus before counting the spots in peptide stimulating wells, the standard of useable 
plate we definited is that only those positive control wells spots are the biggest by 
eyes, negative control well spots can be counted easily, and the numbers of spots 
in serial wells almost were consistent with relevant serial dilute cell numbers. By 
this standard, we found 27 donors are not useable. The background spots are 
almost as same as their PHA wells. The spots were also almost no different from 
all the peptide wells. All the peptide wells lost the consistence with the cell 
numbers in the wells. The cause of high background was not completely clear; 
maybe it was relevant to individual difference of samples or contamination. To 
ensure the reliable results, we rejected these samples. The typical figure of Elispot 
assay were listed in the appendix 7.3. 
After counting all the samples, we checked if our counting was consistent by 
randomly selecting 11 plates to repeat the blank wells (Table 10). The intervals 
were from 1-6 months. The number of spots were not varied too many, statistic 
showed there was no different between two times counting (pair T test). Then the 































































































































































































































































































































































































































































































































































































































































































































































Chapter 3 Results  
As the design, there were 3 continuously cell numbers for each peptide 
stimulating. The numbers of cells were 5，2.5，and 1.25 x 10^ cells respectively. 
So in nomal condition, the relationship of spots in the three negative wells should 
be "double". Then we took advantage of the relationship to check how the data 
compliance was in the experiment. 
As in the EXCEL spreading file (Appendix 1), the useable samples were 133. 
Blank spots ranged from 0-40/10^ (table 10)，the number of spots was highly 
consistent with previously studies which showed that the spots number ranged 
from 0-33 spots/10^ PBMC (mean 9) in EBV studies [141]. 
Table 11 showed the Blank mean, standard deviation, median of the series diluted 
blank spots of three cell numbers was 10 士 lO/SxlO^, 6 士 6/2.5x10^ 3 士 5/1.25xl05, 
the median was 7, 4, 2 respectively. The almost double relationship again proved 
the data compliance was good. The line relationship of cell number and number of 
spots was established (P<0.05) (P-0.0472, 0.0449 respecitively) (Table 11, Figure 
3-1) indicating the frequency/lO^ in the study was reliable. 
I 
Table 11 Blank cell numbers and spots 
PBMC numbers Median Mean Standard deviation 
502000 7 To 10 
255000 4 6 6 
131000 2 3 5 
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Figure 3-1 Linear relationship of background spots and cell number 
• median • mean Linear (mean) Linear (median) 
10 R2 = 0.99§^   
s — ^ 
0 -I , 1 1— 1 1  
0 100000 200000 300000 400000 500000 600000 
Cell number 
Then, which peptide stimulating wells are positive? Since the responding wells 
were not exactly same as the positive control wells, then what number of spots in 
the peptide wells was positive was a problem. In comparable trials, it is very easy 
to compare the frequency from “before” and “after” [234]. But in independent 
donors for one time assay，this hadn't been solved completely. In convention, the 
positive spots should be significantly higher than those in the negative wells [235-
238]. We adopted this way and calculated the approximate normal range of the 
blank spots，the positive standard to each individual was the high value of 95% CI 
of the backgrounds to each sample after comparing the spots in the peptide wells 
with the spots in the corresponding negative wells of each individual, 
Such confidence interval (CI) level gave a "perfect" way to define the positive 
standard. But it was not enough to answer if the response was real from biological 
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view, because the sensitivity of our test was not known. A whole "real response 
cutoff’ needed to be confirmed in specific study. 
Most of the researchers combined "empirical" and statistic ways to confirm cutoff 
levels. Lalvani used minimum of 5 SFCs/5xlO^ and additionally, the number was 
at least twice that in negative control wells [216]. Semets used 10 spots greater 
than negative controls and at least 25 spots /2.5xl0^ for positive definition [233；. 
In cytomegalovirus study, Elkington used three times above negative control wells 
as positive [239], and Addo added another limited condition of >50/10^ SFCs 
•240]. Draenert combined at least 50 SFC/10^ PBMC and at least three times 
above background as positive in HIV study [241: • 
All of these papers did not talk the reasons; we guessed they might be based on the 
sensitivity of the Elispot assay under different experiment conditions. In general, 
the limit of sensitivity of ELISPOT assay is 1 out of 100,000 [242]，the specificity 
and positive predictive values is 90-100% [237]，but in a specific experiment, the 
sensitivity shifts dependent on medium, human serum, antibody pairs, plate 
composition or chromogen substrates and stimulating ability of peptides. In some 
studies, the detectable level is 20-30 antigen-specific T cells per 100,000 cells 
[243] while others think the level is as low as 1 or 2 cells out of 100,000 or 
200,000 [141, 210]. One of the most recent excellent study in HIV 15 mer 
peptides proved that the threshold of detection of a positive response is �50/106 
[244]. At the same time, we noticed that previously EBV study of Elispots showed 
that the minimum frequency of T cells in persistent infection is about 20-100/10^ 
PBMC [245]. According to these investigations, we believed 10-50/10^ is 
approximately true sensitivity in Elispot assay. 
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Then we went to investigate if the sensitivity of our assay was in this range. 
Testing showed that the background spots in each cells number wells in these 
donors were not normal distribution (SPSS, normal testing, data not shown). Thus 
the medians of these spots in relevant wells (7，4，and 2 respectively) represented 
the overall level of the assay. The figure 3-1 extropolated the median of SFCs are 
14/1,000,000. That meaned if the number was lower than 14/10^ even the SFCs in 
peptide wells were higher than those of statistic high value of background, the 
response was still a false positive. On the other side, SFC/10^ was higher than 14 
but lower than high value of 95% CI is also a false positive. 
One study involed EBV specific CTLs study showed 20/10^ is reasonable cutoff. 
Using this standard, authors found the positive results were consistent with about 
70% of all samples between several laboratories [209；. 
Base on the investigations, we also used cutoff, 20/1,000,000 as the threshold, and 
at the same time the spots in the peptide wells were significantly higher than its 
high value of 95% CI negative controls were deemed to be positive. The strict 
standard may leave out some low, real positive response, but it guarrented the 
reliability of real positive response. The cutoff of sensitivity on whole level was 
almost as same as previously study [209，245, 246]. 
To t ake a dvantage o f t h e b iggest i nformation of the data, we p icked out all the 
donors' highest cell number wells as analysis in this study. Using the cutoff we 
investigated above, those positive frequencies were listed alone (Appendix 2). 
Those negative response data listed as a "dash" in the form，"n.d" in the form stand 
for “not done，，in the experiment. Our analyses were based on these data. 
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We characterized the response as three parts by HLA restricting alleles to 
investigate the epitope choice in each specific allele population qualitatively; 
HLA-All, HLA-A2, and non-All, non-A2 restricted HLA alleles. The same data 
were grouped again to investigate the epitopes choices quantitatively by the 
response strength. 
3.2 CTLs Response to Each Epitope in the Population 
3.2.1 Positive Response to A l l Restricted and Mutant Epitopes in the 
Population 
In this part, three wild-type epitopes, AVF, IVT, SSCS, were tested in the 
experiment. In addition, type 2 sequences of the two epitopes, 6 AVF mutants and 
5 IVT mutants were also tested at the same time under the same condition. 
Whether these variant epitope sequences are immunogenic or silent in Chinese 
donors provided evidence regarding A l l epitope polymorphism among EBV 
strains and the immunological implications of such polymorphism. 
Table 12 summarized the positive responses to at least one of the peptides. 47 out 
of 133 donors' responded to one of Al 1 epitopes. In 47 positive donors, 37 out of 
133 donors responded to SSCS (22 -472 /1mean= 90±92/10^ Md=54/10^). 12 
out of 117 donors responded to AVF (SFC, 26-285/106, mean= 108士86/106， 
Md二93/106). While there was only 1 out of 116 donors (Hkcont257) responded 
to IVT (189/106). 
Because of large number of tested donors, A l l donor frequency was very likely 
same as actual frequencies in the population theoretically. That is, there had 
contained about 56% of Al 1 individuals in this study. This was proved further by 
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the internal control epitope, SSCS. In another study [246], half these A l l donors 
(identified by HLA typing) recognized the epitope and thus predicted overall 28% 
of the whole Chinese population (half of 55%) showed a SSC response. We tested 
this epitope in 133 donors, so the predicted number of HLA-Al 1 donors were 
about 74, the observed positive frequency of response to the epitope was 37 out of 
74 (50%), which was highly consistent with Midgley's data (55%). Base on the 
reliable speculation, we can conclude that AVF responder covered 1 8% of A l l 
donors theoretically (12 out of 66)，IVT elicited responses in less 1% of the 
population (1 out of 66). 
The study of Midgley's showed that, in 74 Chinese EBV isolates, IVT was 
mutated in almost all donors (the observed variants are IVT/L2, IVT/L5, IVT/N9, 
IVT/T9 and IVT/R9), and AVF mutated in about 75% cases (AVF/Pl, AVF/A2, 
AVF/N4, AVF/S1F2, AVF/P1L2 and AVF/S1L2) [116, 123, 179，246], thus it was 
very likely that at least 95% of A l l positive individuals tested in this study (ie at 
least 60 donors) would have been carrying an EBV strain with a variant IVT 
epitope and at least 75% of these individuals (ie at least 50 donors) would have 
been carrying an EBV strain with a variant AVF epitope. That is, less than 5% and 
-25% Chinese donors carry wild IVT and AVF, thus the reasonable positive 
Elispot response should be same as the levelif the resident of two epitope's 
distributions were same as the whole population. 18% positive frequency of wild 
AVF and only 2% positive frequency of wild IVT in this study are highly 
consistent with the study (P>0.05, chi-square test). So where AVF responses 
(18%) are seen, they very likely come from the minority (25%) of Chinese 
individuals who carry a virus with a wild-type AVF epitope [246]. The findings 
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of responder to AVF and IVT were very significant different are due to different 
wild frequencies of two epitopes in the population. 
To variants of IVT, There were only 2 donors with 2 positive response times to its 
variants. Hkcont 2163 had a response to R9 mutants (24/10^), and Hkcont 2143 
responded to L2 mutants only (38/10^). The response of IVT was quite rare and 
very weak. So it is clearly showed that, in total, IVT variants in the study cannot 
elicit the response. To AVF, 0-16% HLA A l l donors responded to different 
mutants (Table 15). In these responses, no donors responded to P1L2，only one 
donor responded to S1F2. Another higher response times were 10 with the mutant 
A2 while N4 and PI had 6 and 4 times response in donors. This was consistent 
with another study in this population [246]. On the other side, 10 out of 14 donors 
had cross-reactive to S1L2, which is different from the previously study [246；. 
Our question to AVF was if these responses were the “true，，variant responses. 
Lookingback the data (table 12)，most of variant AVFpositive donors had the 
responses to wild AVF (12/14). As we suspect that these donors carry the wild 
type of the epitope, so the results of these positive mutated AVF frequencies were 
not "true" response. There were only two donors responded to variants of AVF, 
Hkcont 263 responded to S1L2 (26/10^), and Hkcont2128 responded to PI 
(44/106). Thus，in total, all the variants of AVF also induced no-response. 
Interestingly, in 44 positive responses to one of wild type epitopes, 39 donors had 
incompatible response to two epitopes, AVF or SSCS (Table 12). It seems that 
two epitope responses were competed. Note midgley's study also showed the 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3 Results  
3.2.2 Positive Frequencies of A2 Restricted Epitopes in the Population 
The A2 frequency is about 54% in southeast Chinese population, there are at least 
four main A2 subtypes in the population, and the peptide binding motifs between 
the subtypes have minor variation. But the effect ofsubtype polymorphism on 
EBV epitope choice is not known. There were 12 A2-restricted epitopes. Most of 
the epitopes (8/12) are A201, 3 of them are A203, one of them is A206. 
51 donors responded to at least one of A2 restricted epitopes (Table 16，17). The 
frequencies were from 22 (YLL)—809(YVL). T able 16 only 1 isted 1 2 parental 
epitopes. From the strength of responses, we found except for frequency of YVL 
(Mean, 259/10^), the responses to these epitopes (whatever mean or median 
frequency) were between 20-120/10^. The results were consistent with the 
previously study which showed that the frequencies of T cells specific for EBV 
latent Ags are about 20-100/10^ PBMC in healthy virus carriers [245]. Further 
analyses of data showed that the response strength to lytic epitopes was the 
strongest (Md-80/10^), lytic response was stronger (mean, 149/10^) than latent 
(mean, 82/10^) on the whole (P=0.0113, wilconxon test). To latent epitopes, 
LMPl, LMP2 responses always were intuitively lower than other epitopes. 
The positive responders to each epitope were different but in total they were lower. 
One of A203 epitope, VLK, was the highest (29 out of 133 donors). Another 
A203 restricted EBNA-LP epitope, SLR, This epitope is from Chinese donors and 
A203 restricted. Previously study showed the epitope could induce CTL-CTL 
lysis [147]. 9 out of 93 donors responded to the epitope indicated the 
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immunogenicity is higher than most of other A2 epitopes. Lytic epitope responses 
were relatively more in these heathy donors, GLC, TLD, got 9 and 8 responses out 
of 1 33 donors, and 5 out of 117 donors mounted the response to Y VL. LMP 
epitopes FLY, LLW, got 8 and 7 out of 133 donors. YLQ, only got 5 out of 133 
donors, other epitopes such as YLL，LLS，LTAg only got 1 or 2 positive response 
(Table 14). 
As shown in HLA-Al 1 part, the large number of randomly selected donors was 
very likely shown same HLA frequencies as the whole population's, thus we used 
the HLA frequency data in the population [154, 155] to calculate the positive 
frequencies of epitopes in specific HLA allele populations. First, we evaluated the 
theoretically number of A2 donors to each epitope. For example, for CLG, there 
were 133 donors tested in the experiment, and A2 occupy about 54% in the 
population, then there were about 133x54% =72 donors theoretically in this study, 
the positive frequency of CLG in A2 population was 4/72. Through the same way, 
we also evaluated the positive frequencies in theoretically number of A2 subtype 
donors [156，158], the results listed in last two rows of Table 15. 
In total, positive frequency of VLK was the highest (40%), GLC, YVL，TLD, 
covered relatively high positive frequencies in the population. Since the 
calculation was in the theorectically Al population, the results of the positive 
frequencies indicated that only small fraction of A2 donors responded to these 
epitopes, thus indicated all of these epitope elicit weak and rare responses in A2 
population thus they are largely high A2 specific. 
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To subtype positive frequencies, one unexpectly result was, in 51 A2 donors, 29 
donors responded to VLK. Since there were only � 1 7 A203 subtype donors 
theoretically existed (23% of A2), 29 positive donors definitely indicated 
additional 12 donors are not A203 (Table 15). VLK responders also responded to 
other subtype allele restricted epitopes, such as HKcont2160，Hkcont291 had the 
cross reactivities to A201 restricted eptiope, GLC (A201); Hkcont248, Hkcont 
2132 had the cross reactivity to A206 restricted epitope, LTAg (A206); 
Hkcont2150, Hkcont2194, Hkcont2154 had the cross response to YLQ (A201), 
etc. So we speculated these responders could possibly be A206 and A201 since 
both LTAG responders (Hkcont 2 132, 248) also responded to VLK and several 
donors responded to different A201 restricted epitopes. Amino acid sequence of 
VLK fits well to A207 allele binding motif, thus there are 14 donors in this study 
only have the responses, some of them maybe were this type. In contrast, SLR 
(A203 restricted) responses were less common than VLK responses. 6/9 SLR 
responders also responded to VLK. It seemed the epitope is largely A203-
restricted. But it was hard to make definite conclusions regarding SLR except that 
it is probably the second most immunogenic A2 epitope in Chinese. Another 
epitope, LLS (A203) seldom elicited the response thus it is a highly A203 subtype 
specific epitope. 
Cross-recognition can also be speculated in A201 restricting epitopes. As in the 
table 14，26 donors responded to at least one of A201 restricted epitopes. But there 
are only � 1 7 A201 donors, so some A201 restricted epitopes were clearly 
recognized by other alleles. The multirecognition may exist in FLY, and LLW. 
Previously study showed LLW appear less immunogenic than CLG in Caucasians 
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101，102], but the data here showed LLW responses were likely broader than 
CLG (7/133 vs 5/133). There were also slightly more responders to FLY (8/133 
donors). If these data can represent the whole level in the population, the 
difference may due to two epitopes be immunogenic on another subtypes as well 
as A201 because most Caucasians are only A201. Note that three individuals 
(Hkcont 2 114, 2 145, and 2 164) responded to FLY and VLK (A203) suggesting 
that FLY might share a restriction element with VLK (possibly A203?). But this is 
difficult to be sure about because some donors might be "double A2" ie positive 
for A201 and A203 subtype. 
The responses to two specific epitopes, CLG (A201), YLL (A201), and their 
mutants are also interesting. There were only 5 responders to CLG or its variants, 
since about 17 donors (12% of 133) will be A201, the positive number of this 
response probably reflected the fact the CLG variant epitope sequence is not 
immunogenic in the context of A203, A206 or A207 subtypes. So all the CLG 
responses could be explained by the presence of A201 positive donors and indeed 
3 of the 5 CLG responders (Hkcont 2115, 2171,257) also responded to other 
known A201 epiotpes like FLY or LLW (table 14, table 16). 
YLL (A201) responses were rarely seen. Only 2 out of 133 donors responded to 
YLLEILWRL in this study which contains the sequence of Caucasian virus strains. 
The results indicated the epitope response is highly subtyping allelic specific. But 
it was hard to make firm conclusions here because the variant YLL sequences 
common in Chinese viruses, YFLEMLWGL, YLLEMLWRL, were not 
rigourously tested (only 16 samples tested, one donor recognized variant 3， 
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YLLEMLWRL, data not shown). Previously study showed both epitopes can be 
recognized by several A2 subtype alleles (A201, A202, A203, A204，A206 for 
YLL, A201, A206, A207, A209 for CLG), thus the two epitopes were regarded as 
supertype peptides [145, 224]. Our results showed the two epitopes are unlikely to 
be supertype peptides in southern Chinese since they showed the highly subtype 
specific responses in the panel. Another LMPl epitope, YLQ, is probably a weak 
epitope restricted by A201 only because there are only 5 responders while there 
maybe were -17 A201 donors. Furthermore, 3 of the 5 YLQ responders, Hkcont 
2164, 2171，257, also responded to A201 epitopes like CLG, LLW or FLY. 
LTAG (A206) responses were very rare (2 out of 130). Since A206 theoretically 
number of donors was about 6 � 1 7 (8-25% of A2), the low positive frequency of 
the epitope probably indicated this is a weak epitope restricted by A206 only. 
Responses to the lytic epitopes GLC, YVL and TLD were interesting. They are all 
A201 restricted epitopes in Caucasians. 3 lytic epitope responses covered 19 
donors in this study. B ut there existed iincompatible responses in same donors 
among them. That is, most of donors only recognized one of lytic epitopes. Only 
2 donors (Hkcont 2115, 2171) had muti-recognitions to the lytic epitopes. For 
GLC and YVL, lower in magnitude than would be expected from their responses 
in Caucasians. More than half of the responses seen to GLC and YVL came from 
Chinese donors likely to be A201 because they also saw A201 restricted epitope 
responses of CLG, LLW or FLY. So the TLD (A201) responses might be 
presented by a different subtype in Chinese because it is usually very low or absent 
in Caucaians [227] and it may be significant that 3/8 responders to TLD (all three 
lacking a GLC or YVL response) also responded to VLK (A203). 
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In total, the positive frequencies of A2 restricted epitopes in A2 population ranged 
from 3-40%, so the responses are largely A2 specific. The positive frequencies of 
the epitopes responses in A2 subpopulation ranged from 12-75% except VLK, so 
most of the A2 restricted epitope responses are largely highly subtype specific 
(table 15). 
Table 14 CTLs response to at least one of A2-restricted epitopes (SFC/10^) 
" " " J ^ ~ A 2 O T “ ” A 2 0 1 A201 "A201 J ^ J ^ A 2 0 3 A206 
Epitopes ^ L L W F L Y Y L Q T L D Y L L ^ ^ L L S V L K S L R L T A g 
Hkcont208 I —_ : I t^ I nd I ^ ” I “ 
Hkcont211 _ _ _ _ nd _ _ nd _ 29 nd _ 
Hkcont220 25 _ _ nd _ _ nd _ 55 nd _ 
Hkcont222 _ _ _ _ n c l _ _ n d _ _ n d _ 
Hkcont230 59 _ 81 _ — _ _ 131 nd — 
Hkcont231 _ _ _ _ 4 8 _ _ _ _ _ n d _ 
Hkcont236 _ _ _ _ _ _ _ _ _ 48 n d _ 
Hkcont241 _ _ _ 120 _ _ - 1 3 8 n d _ 
Hkcont248 _ _ _ _ _ _ _ 一 一 80 nd 60 
Hkcont251 _ _ _ _ 5 1 _ _ _ _ 6 7 n d _ 
Hkcont252 _ _ _ _ 3 6 _ _ _ _ _ n d _ 
Hkcont254 _ _ 2 8 _ _ _ 2 2 _ _ _ n d _ 
Hkcont257 _ _ 97 61 _ _ _ 275 _ _ nd _ 
Hkcont258 _ 3 1 5 9 _ _ _ _ _ _ _ r i d . 
Hkcont263 _ _ _ _ _ _ _ _ 28 _ n d _ 
Hkcont286 _ _ _ _ 100 _ _ _ _ _ _ _ 
Hkcont289 — - - - - 223 _ 
Hkcont290 _ 3 5 _ _ _ _ _ _ _ 86 _ _ 
Hkcont291 _ _ _ _ _ _ 49 — — 64 — -
Hkcont294 _ 21 _ _ _ _ _ _ _ 一 - — 
Hkcont2110 _ _ _ _ _ _ - — — 40 50 -
Hkcont2113 _ _ _ _ _ _ - - - 40 — _ 
Hkcont2114 _ _ 24 _ _ _ _ _ _ 41 67 _ 
Hkcont2115 44 29 97 _ 73 _ 468 809 _ — _ _ 
Hkcont2120 _ 45 _ _ _ _ _ _ _ - - -
Hkcont2122 — _ 一 - 53 — -
Hkcont2123 _ _ _ _ _ _ _ - - 2 2 2 _ _ 
Hkcont2125 - - 柳 ― -
Hkcont2126 — _ _ _ - - 一 - - 1 6 2 _ _ 
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Epitopes C L G [ I w ^"YLQ~~TlD GIClI^"~VLK — S L R L T A g 
Hkcont2127 : : : : : “ ： ： ： ： _ _ — 
Hkcont2129 _ _ _ _ _ _ _ _ _ 100 _ _ 
Hkcont2132 _ — — _ — _ — — _ 78 164 51 
Hkcont2134 _ _ _ _ _ _ _ _ _ 143 _ _ 
Hkcont2136 _ _ _ 372 197 — — _ _ _ 
Hkcont2138 _ _ _ _ _ _ 136 _ _ _ _ _ 
Hkcont2140 _ — _ — _ 114 — — _ — 
Hkcont2142 _ _ _ _ _ _ _ _ _ 59 49 _ 
Hkcont2143 _ _ _ _ _ _ _ 31 _ _ _ _ 
Hkcont2145 _ 25 一 79 384 278 
Hkcont2146 _ _ _ _ _ _ 64 _ _ 134 _ _ 
Hkcont2150 _ _ _ 3 5 _ _ _ _ _ _ 65 _ 
Hkcont2151 _ _ _ _ - _ - - - - 72 — 
Hkcont2154 _ _ — 32 — _ — 75 24 _ _ 一 
Hkcont2155 _ _ 28 _ _ _ _ _ _ _ _ _ 
Hkcont2158 _ _ _ _ _ _ - - - 37 — — 
Hkcont2159 _ _ _ _ _ _ _ - - 255 _ _ 
Hkcont2160 _ _ _ _ _ _ 42 _ _ 44 _ _ 
Hkcont2161 _ _ _ _ _ 22 _ _ _ _ _ _ 
Hkcont2162 — _ — — _ - - - 40 116 — 
Hkcont2164 _ 96 84 8 4 _ _ _ _ _ 4 1 _ _ 
Hkcont2171 91 45 118 — 123 107 一 一 一 _ 
Table 15 Summary of the Table 14 
~ """""A201 A201 A i o i f ^ l A201 A203 A206 
Epitopes CLG LLW FLY Y L qT l ^L L GLC YVL LLS VLK SLR LTAg 
NO. of positive 4 7 8 5 — 8 了 2 29 9 2 
Tested samples 133 133 133 133 117 133 133 117 133 133 93 130 
NO.% in this study 3 5 6 4 7 2 7 4 2 22 10 2 
Estimated A2 donors 72 72 72 72 63 72 72 63 72 72 50 72 
(NO.%) (6) (10) (11) (7) (13) (3) (13) (8) (3) (40) (18) (3) 
Estimated A2 subtype 17 17 17 17 17 17 17 15 17 17 12 6 
donors (NO.%) (24) (41) (47) (29) (47) (12) (53) (33) (12) (171) ( ^ ) J 3 3 ) 
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Table 16 CTLs response to CLG and its variants 
Sample ID BIk-freq CLG CLGv1 CLGv2 
Hkcont220 5 25 _ -
Hkcont2115 4 44 _ 一 
Hkcont230 9 59 47 _ 
Hkcont2171 20 91 48 _ 
Hkcont257 5 一 一 99 
3.2.3 Positive Frequencies of Other HLA Allele Restriction Peptides 
Again, we extended our work to investigate some other HLA alleles response 
including A23，A24, and A25 restricted epitopes, PYL, TYG，TYGSL and VMS. 
Several kinds of HLA-B including B40, B38，B58, B63 and B27 restricted 
epitopes, YHL, lED，lEDSI, VQP, VSF, and WTL, were also included. Most of 
these peptides are mainly derived from the LMP2 protein sequence, and they have 
already been identified as immunodominant epitopes in relevant Caucasian donors. 
In Chinese populations, some HLA alleles that are closely related to the originally 
reported Caucasian restriction element, so we ask if the epitope can elicit the 
response in those relevant Chinese donors. 
Indeed, the epitope response can be detectable in Chinese donors, but their 
distributions are totally different. Table 17 summarized the detailed information, 
the relevant calculation were listed in Table 18. 
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Table 17 CTLs response to at least one of other HLA alleles restricted 
epitopes (SFC/106) 
A23 A24 A24 A25 827 838 840 840 846 858 863 
Epitopes PYL TYG TYG-SL VMS RRRW YHL lED IEDSI VQP VSF WTL 
Hkcont223 nd nd nd 69 
Hkcont224 nd nd nd 78 
Hkcont228 nd nd 578 
Hkcont230 49 nd 391 591 31 
Hkcont231 66 62 nd 578 
Hkcont241 nd 76 152 
Hkcont248 nd 42 
Hkcont250 nd 35 
Hkcont251 33 135 179 nd 239 299 
Hkcont254 24 24 nd 48 100 34 
Hkcont257 133 nd 43 27 nd 
Hkcont262 nd 38 66 46 
Hkcont267 114 
Hkcont268 51 36 
Hkcont269 57 21 98 25 
Hkcont277 80 47 42 
Hkcont283 206 146 
Hkcont285 186 202 
Hkcont286 97 92 
Hkcont290 145 
Hkcont297 52 97 444 30 
Hkcont2100 126 122 61 2 
Hkcont2106 27 625 
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‘ A23 A24 A24 A 2 5 ~ B 6 3 
Epitopes PYL TYG TYG-SL VMS RRRW YHL lED lEDSI VQP VSF WTL 
Hkcont2128 42 7 I I " I I T " 
Hkcont2129 709 _ _ _ _ _ _ 677 _ _ 
Hkcont2136 30 230 _ _ _ 489 347 — — 314 
Hkcont2139 140 _ 一 _ _ _ _ 174 _ _ 
Hkcont2140 49 _ _ _ _ _ _ 481 _ _ 
Hkcont2144 102 41 — _ 92 _ _ _ _ _ _ 
Hkcont2148 135 56 _ _ _ _ 106 _ _ _ 
Hkcont2149 63 86 _ — _ — — — -
Hkcont2150 _ — _ _ _ — _ _ 249 160 
Hkcont2151 _ — 30 _ _ — _ _ 132 130 
Hkcont2152 _ _ 一 一 一 一 21 一 — 一 
Hkcont2153 _ 一 一 _ _ _ _ 272 _ _ 
Hkcont2154 _ 一 一 _ _ 51 39 _ _ 39 
Hkcont2163 _ _ — _ _ _ _ 72 518 215 
Hkcont2164 _ _ _ _ 5 5 _ 一 一 _ _ 
Hkcont2165 一 一 一 一 — 89 一 一 一 _ _ 
Hkcont2166 _ 一 _ 一 _ - - 一 511 — 
Hkcont2168 _ 一 — — _ - - 一 197 — 
Hkcont2173 _ _ _ _ _ — - _ 543 _ _ 
Table 18 Summary of Table 18 
~ “ """" A23 B40 B46 B58 B63 
Epitopes PYL 
SL  
l ^ ^ r ^ f p ^ ^ 5 3 r " l 2 12 11 19 12 
Tested samples 133 133 133 117 127 93 133 133 133 133 125 
NO.% in this study 7 6 3 4 2 3 9 9 8 14 10 
Estimated 广 ^^  . 
Allele-specific donors 1 36 36 0 5 9 46 46 36 17 0 
Estimated postive 汽八 ^^ 
frequencv% 1410 22 11 3885 58 32 26 26 30 J H ^ 
Using the same way to calculate the positive frequencies in specific population 
which gave us the diversified results. As in the table 20，VQP (B46) showed 
response in B46 population (30% theoretically), YHL (B38) also covered about 
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33% of B38 population theoretically. lED (B40) and its variants, lEDSI, showed 
same breadth of immune response to B40 donors theoretically (26%) indicating the 
change of the amino acids in the epitope did not change the immunogenicity, 
which was consistent with the previously reports [101]. Interesting results was 
TYG and TYGSL (A24 restricted), thus previously study showed the amino acid 
change in the epitope did not change the immunogenicity of the epitope [101], the 
positive frequencies were 22% and 11% respectively in this study indicating the 
the change of amino acid in the epitope may change the immunogenicity (P<0.01， 
chi-square test). Since all these positive frequencies are relatively low thus 
indicated that these epitopes are largely allele specific. 
RRRW, which restricted by HLA-B2704, the allele is one of two B27 alleles in 
South East Asia [118]. Furthermore, previously study showed the epitope is a 
B2704 subtype specific epitope [118]. Our data showed there were only 5-6 B27 
donors in this study theoretically, it was believed that B2704 donors in this panel 
were less than B 27 donors theoretically, so the immunogenicity of the epitope in 
the B2704 population is very high even there are only 3 positive donors. 
There were only 1 A23 and A25 donors theorectically in this study, but there were 
9 and 5 donors responded to these two epitopes, PYL (A23)，VMS (A25)， 
respectively, the positive frequencies of two epitopes were 1410%, 3885%, 
respectively, the “impossible，，predicted frequencies indicated there were a lot of 
other HLA alleles recognized the epitopes. 
Mutirecognitions also existed in two other epitopes, WTL (B63). Theoretically, 
there was no or 1 B63 donor in this group, but there were 12 donors responding to 
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this epitope. These multirecognitions will be addressed and likely explanations 
were given in Discussion. 
3.3 CTLs Response Frequencies Categorized by Proteins 
After checking the breadth of epitopes immunogenicity, we recollected the data as 
CTLs response strength to each epitope sorted by proteins. 
3.3.1 CTLs Response to LMPl, LMP2, EBNAl Epitopes 
These protein sources epitopes were put together because they are all expressed by 
NPC tumor cells. So far, we don't know how strong of the epitope response 
should be suitable in epitope-based therapy to NPC. So the data here provided the 
baseline information of epitope response strength. 
650/0 NPC tumor cells can be detected with expression of LMPl protein [247]. In 
Caucasians, 55 to 60% of donors CTLs can recognize the LMPl epitopes [248], 
but the protein is poor immunoegenic, and seldom elicits the immune response in 
individuals [145, 249]. As shown in Table 20，5 out of 133 donors' respondeds to 
YLQ (A201), 2 out of 16 donors' responded to YLL (A201). The frequency 
ranged from 32-197/10^ YLL was resported as supertype epitopes because a lot 
of A2 subtypes recognize the epitopes in Caucasians [145]，but the extensive 
sample tested in this study had more persuasive proof this is a very weak epitope 
and maybe highly A201 subtype specific epitope. 
To NPC and HD, the malignancies don't express EBNA3 family [44，143]. 
EBNAl cannot be presented and processed via HLA class I pathway [127，228]. 
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Since LMPl protein seldom elicits the specific CD8+ T-cell responses [145]， 
LMP2 epitopes then were focused for epitope-based therapy. 
We had 16 LMP2 epitopes, 68 donors responded to at least one LMP2 epitope. 
These donors covered all the positive donors of LMPl. Their frequencies were 
ranged from 22-709/10^ except VLK (29-384/10^), Table 19 showed A2 restricted 
epitope positive frequency and response strength was a little bit lower than non-A2 
restricted epitopes intuitively. For example, the strongest response strength of 
non-A2 epitope, lEDSI, was 21-581/10^ (mean, 156) while the strongest response 
strength to A2 epitope, YLL，was 22-197 (mean, 109). The frequency of non-A2 
restricted epitopes, SSCS, WTL, lED, PYL is higher than most of A2 restriction 
epitopes such as YLQ, FLY, LLW (Table 19). 
3.3.2 CTLs Response to EBNA2，EBNA-LP Epitopes, EBNA3 Epitopes 
There was only one EBNA2 epitope in this study, B3801 restricted epitope, 
YHLIVDTDSL (YHL), and the epitope in Caucasian viruses (YHLIVDTDSR) is 
highly immunogenic. Previously study showed CTLs isolated from one HD 
patient are directly against this epitope, and the Chinese version in this study is that 
the sequence of the epitope is different at position 10, L to R substitution [230]. 
The response strength is from 31-89/106, indicating the epitope is a weak epitope 
in Chinese population. 
There was only one EBNA-LP epitope in this panel: SLR. Previously study 
showed there are occasional response to EBNA-LP [112，121，122]，later, Lee 
[147] defined the epitope in Chinese donors, the function of EBNA-LP in the 
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transformation process is poorly understood, in the B cell model, the first viral 
proteins to be detected following infection are EBNA-LP and the viral 
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proteins are high immunogenic in the population. As shown in Table 20, the 
frequency of SLR ranged from 49�278/106. The results here indicated that SLR is 
relatively stronger in the population. 
4 EBNA3 family epitopes positive response were collected. Base on the total 
results, 42 donors recognized at least one of 4 epitopes. The frequencies of the 
peptides ranged from 21�625/1O^. 
Previously study showed that EBNA3 epitope are always the immunodominant 
epitope in individuals [113，115-119]. Our results again proved this some extent in 
this study. Comparing the frequency, VSF possessed the highest frequency (66-
625/106 mean: 302/10^), AVF, VQP was also relatively higher (108/10^ 229/10^ 
respectively), although IVT was rare to see the response (1 out of 117)，the 
response strength was quite high (188/10^). 
Table 20 Response Strength of EBNA3，EBNA2 and EBNA-LP epitopes 
(SFC/10^) 
B58 "1^46 ATI A11 B38" A203 
Epitopes ” ” e b h a ^ 
VSF VQP AVF 丨 VTwt1 YHL SLR 
NO. of positive 19 11 12 1 3 9 
Total sample 133 133 117 116 93 93 
Frequency range 66-625 22-677 22-356 188 31-89 49-278 
Median 204 232 86 _ 29 83 
Mean 302 229 108 _ 58 120 
SD 197 97 93 — 55 72 
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3.3.3 CTLs Response to LYTIC Epitopes 
Lytic epitope responses are thought to predominate in primary infection. In 
persistent status, EBV lytic proteins are also the frequent targets for CTLs [99, 
114，226]. In HLA-B8-positive donors, EBV specific CTLs are frequent directed 
against immediate early and early lytic epitopes [99, 114, 226]. All of three lytic 
epitopes, YVL, TLD and GLC, in this study are A201 restricted. These epitopes 
are from EA antigen, the antigen expressed in the early phase of the EBV lytic 
cycle before the viral replication [15, 16]. Studies showed response to GLC, 
which derived from early lytic protein BMLFl, were maintained through latency 
102]. Thus it is interesting for us to know how strong of the lytic response to 
other two epitopes. Again, the data may provide the baseline data of CTLs 
response strength to lytic epitopes in persistent infection. 
3 lytic epitopes responses covered 19 donors in this study. The frequency ranged 
from 21�809/ 10^ From the Table 21, the strongest response was YVL, next was 
GLC. But this was not being sure because the positive numbers of responders are 
all quite rare. The interesting thing was TLD, the response strength of this epitope 
in Caucasians are rare and obviously weaker than GLC. But in this study, the 
response strength to TLD was almost as same as GLC. This indicated that TLD 
could be presented more efficiently by another A2 subtype. Indeed, most of 
donors only recognized one of lytic epitopes. Only 2 donors had muti-recognitions 
to one of other A201 lytic epitopes (Hkcont 2115, 2136) but TLD is very 
relatively weak. 
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Table 21 Response Strength of A201 Restricted Lytic Epitopes (SFC/10^) 
丨 BRLFT 一 BMRF1"“™“— 
Epitopes ^ " W L "“ TLD 
Positive NO. 9 ^ 8 
Total sample 133 117 133 
Frequency range 22-468 31-809 36-372 
Median 79 107 77 
Mean 122 259 110 
SD 136 321 110 
3.4 Summary 
In summary (Table 22)，87 donors had positive response to at least one of these 
epitopes while 46 donors had no response to any of these peptides. 
Table 22 “No. of epitope response" and "No. of donors" 
" " " r e s p o n d e d ° i ^ i i S ^ — No. of responded donors  










10 1 _ 
These epitopes are from EBNAl，EBNA2, EBNA3, EBNA-LP, LMPl, LPM2, 
BZLFl, BRLFl, BMLFl，and BMRFl proteins, so it is interesting to see the CTLs 
response pattern to these epitope on protein levels. 
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Exclude AVF mutants and IVT mutants, most of donors (113/133) had 0-3 epitope 
responses in this study. There were total 276 times positive response in these 
donors. Among these positive response, 92% times responded to latent epitopes 
(252 out of 276)，while 8% times responded to 3 lytic epitopes (24 out of 276). In 
87 positive donors, total 22 response times of 19 donors responded to one of lytic 
epitopes and 86 donors responded to one of latent epitopes. Most of the times, 
126, responded to 14 LMP2 epitopes, 77 times responded to 6 EBNA3 family 
protein epitopes. 29 times responded to 1 EBNAl epitopes, and only 3 times 
responded to 1 EBNA2 epitopes (Table 23). These data showed that the 
immunodominance of EBV epitopes are intuitively consistent with other 
population in previously study [112,116-119, 121-126]. The data here may 
indicate that the influence of epitope choices on the whole level under the specific 
HLA polymorphisms in this population doesn't change. 
Table 23 Response times to each protein epitopes 
？ ” L M P l L M ^ 
E ^ t ^ N a i “ 1 6 3 12 
^^sl^I^^^^tl^ T 3 77 8 126 
^ ^ — — — — ~ 
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4 Chapter 4: Discussion 
4.1 Discussion of A11 Restricted Epitopes 
The present work concerns CTL epitope choice under immune pressure. In some 
viruses, such as HIV, viral progeny carrying mutations in immunodominant 
epitopes appear as CTL escape mutants in HIV individuals progressing to AIDS. 
These arise due to the error-prone replication mechanism of HIV reverse 
transcriptase [250，251]. But for EBV the situation is different. This ancient 
human virus is genetically stable and persists in the immune host by suppressing 
viral antigen expression rather than by mutation. However to what extent CTL-
mediated immune pressure can influence the long-term co-evolution of EBV with 
its host species over many thousands of years is not known. 
HLA-All alleles are unusually frequent in Southern Chinese; the allele is known 
to be capable of eliciting strong CTLs responses against "wild-type" (i.e. B95.8) 
IVT and AVF epitopes in HLA-All-positive Caucasians. Furthermore, previous 
w o r k h a s defined five known patterns of nucleotide change in the IVT epitope-
coding sequence and six known different AVF sequence variants in EBV strains in 
the highly All-positive southern Chinese population [246]. This situation 
provides a good opportunity for studying the possible role of immune CTL 
pressure in selecting what strains of EBV are prevalent in a host population. 
To ask if these resident variants might have been selected by immune pressure, we 
tested the IFN-y release pattern of Chinese donor PBMCs by Elispot assay after 
stimulating the cells by wild AVF, IVT, and full panel of their mutants. We 
predicted that, if resident variants can escape from the immune pressure，CTL 
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responses to the variant IVT and AVF epitope peptides would not be seen in 
Elispot assay in most Chinese donors. Since more than 95% of Chinese isolates 
mutated in IVT, responses to wild type IVT would be very rare in Chinese people. 
However �25o/o Chinese isolates carry the wild-type AVF epitope sequence, and 
so we might expect some evidence of AVF responses in that proportion of A l l -
positive people. 
We studied these questions directly by Elispot assay on randomly collected 
Chinese d onors. W e r easoned t hat, although w e d i d n o t k now t he d onors’ H LA 
types, if we have a large enough study samples, HLA alleles are likely to be 
represented close to their actual frequencies in the whole p opulation. This was 
proved further by using responses to a weak but non-variant HLA-Al 1-restricted 
epitope, SSCS, as a marker of All-positivity in our study samples. Our finding of 
37 out of 133 donors responding to SSCS were consistent with a previous survey 
showing that about 50% All-positive Chinese have a detectable SSCS response 
[246]. We therefore can assume that our study population was generally 
representative and that around 50-55% of donors tested were indeed All-positive 
Base on this assumption, and then only 18% of these All-positive donors 
responded to wild-type AVF and 1% responded to wild-type IVT. 
Formally we need to prove that the 18% AVF responders were infected with a 
virus carrying a wild AVF epitope sequence and that the 1% IVT responders also 
carried a virus with a wild-type IVT sequence. This was not done but, from the 
above argument about the incidence of wild -type AVF and wild-type IVT 
sequences in Chinese virus strains, the implication is that this was the case. The 
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number of wild-type epitope responses is in e ach case what would be predicted 
from the known incidence of Chinese EBV strains with wild-type epitope . 
Apart from these wild-type epitope responses, there may only be 4 real responses 
to variants at most (table 14); two donors recognized variants of AVF and two 
donors recognized variants of IVT without recognizing the respective wild AVF 
and IVT epitopes (Hkcont 2143，2163，responded to two IVT variants L2 and R9, 
Hkcont 263, AVF S1L2, Hkcont 2128，AVF PI , and in these cases the SFC/10^ is 
quite low). So the results clearly showed that almost all the carriers who carry 
variants of IVT and AVF did not have response to any of these variant peptides in 
Elispots assay; this strongly suggests that all of the IVT and AVF variants found in 
those EBV isolates are non-immunogenic in vivo. This is supported by the 
observation that the amino acid changes in these variants are in many cases located 
at anchor sites or auxiliary sites, consistent with the change causing an alterered 
affinity of the variant peptide for the A l l peptide binding groove. The overall 
results suggest that the variants enjoy a selective advantage in vivo in All-positive 
individuals and that their prevalence in the Chinese population may be the results 
of HLA Al 1-restricted CTL pressure. 
Although type 1 viruses are dominant in this population, there are about 5-10% 
Chinese donors carrying type 2 EBV strains; all the type 2 viruses in Chinese 
retain the prototype Ag876 sequence at both the IVT and AVF loci [246]. So in 
this panel, there should be about 6-10 donors who were both A l l positive and 
carried prototype type 2 EBV isolates. The Elispot results here show that there 
was almost no response to type 2 peptides (1 out of 109 donors to AVF and IVT 
respectively); thus it seems likely that the type 2 versions of the IVT and AVF 
epitopes are non-immunogenic in vivo. 
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Interestingly, when tested in the Elispot assay, the 12 donors showing responses to 
wild-type AVF also recognized several of the variant AVF peptides at levels 
ranging from zero (AVF P1L2) to higher than the level seen with wild-type peptide 
(AVF A2) (Table 24). Since these donors are likely to carry a vims strain with a 
wild type AVF epitpope, the results reflect cross-recognition occurring under the 
artificial conditions of high peptide concentration used in Elispot assays. The 
reason may due to the increased chance of cross-recognition by ICRs when 
challenged with high abundance peptide/HLA complexes [178, 252；. 
Table 24 Response strength of CTLs to AVF and its mutants 
AVF wt1 AVF S1L2 AVF A2 AVF P1 AVF N4 AVF Wt2 AVF S1F2 AVF P1L2 
M ^ ^ ^ 49 S ” T a ^ 
AVRAGE 108 103 157 64 117 _ _ -
SD 86 60 119 33 85 _ _ -
Comparing our data with the data from Caucasians [246], we found an interesting 
phenomenon. In All-positive Caucasians, responses to IVT and AVF dominate 
and SSCS-specific responses are only rarely if ever detectable in Elispot screens. 
By contrast, in Chinese donors SSCS was quite often recognized. Thus SSCS was 
tested in 133 donors, of which about 74 (133x56%) are predicted to be A l l -
positive. The particularly high positive frequency of SSCS responders (37/74) is 
consistent with Midgley's data [246]. However, where an SSCS response was 
observed in Chinese donors, this tended to involve individuals who lacked a 
detectable response to AVF (as well as to IVT). In total, it seemed that the 
variation of sequence may influence the CTLs response by “pecking order" [253， 
254]，that is, in the absence of stimulation by IVT, the AVF epitope becomes 
immunodominant, and in the absence of AVF, immunodominance transfers to the 
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third epitope SSCS. However there is another factor that may be important with 
respect to SSCS immunogenicity in Chinese in that，while the minimal 9-mer 
epitope is perfectly conserved in Chinese strains, there is an amino acid change at 
position 10 and this may affect the efficiency of epitope processing; this could also 
help to explain why the SSCS response strength was almost same as the same as 
that to EBNA3-derived epitopes such as AVF (p�0.05 , Wilcoxon test). 
Some researcher have speculated that the lower incidence of NPC in All-positive 
Chinese people versus the All-negative Chinese population may be due to a 
protective effect of the SSCS epitope-induced response since the source antigen of 
SSCS, LMP2, is expressed in NPC cells [101]. The data on SSCS response 
strength in Chinese here indicate that the peptide may be a good candidate for 
immunotherapy in the context of NPC. One interesting possibility is that EBV 
strains with a wild-type AVF epitope sequence will be more prevalent among A l l -
positive Chinese patients presenting with NPC since individuals where the A l l 
response induced by natural EBV infection has focused largely on AVF will have 
little or no natural SSCS immunity to protect against NPC development. 
4.2 Discussion of A2 Restricted Epitopes 
A variety of A2 restricted EBV epitopes have been defined over the last few years, 
those epitopes are restricted by different A2 subtypes. Since A2 subtypes have 
some minor variations in their peptide-binding grooves, we asked if the subtypes 
influence epitope choice in southern Chinese. We found that A2-restricted epitope 
responses are relatively weak when measured in terms of the frequency of positive 
responses and the numbers of epitope-reactive cells detected in Elispot assays. 
The low positive frequencies may due to polymorphism of A2 subtypes because 
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many of the epitopes tested were first reported as restricted through A201, a 
common A2 allele in Caucasians but not so much in Chinese where both A207 and 
A203 are also prevalent. The overall conclusion is that these A2-restricted epitopes 
are most probably not presented by the other Chinese A2 subtypes. 
One example is the LMP2-derived CLG epitope and its Chinese variants. The 
sequence of the epitope is conserved in most Caucasian and African virus isolates 
(whether type 1 and type 2) [101]. By contrast most southeast Asian and New 
Guinean isolates (whether type 1 and type 2) present a different virus mutation 
with a Cys to Ser change at epitope position 1 (CLG vl) with very rare isolates 
encoded a Leu to He change at epitope position 6 (CLG v2). As the positions are 
not one of the anchor residues, it is assumed that this will not interfere with the 
binding of the epitope in the A201 groove. Previously one study showed that 
A201-restricted CTL clones specific for the CLG epitope could recognize the CLG 
peptide in the context of multiple A2 subtypes; but this does not mean that the 
peptide is naturally immunogenic in these other contexts. Our data show a total of 
only 5 out of 133 donors responding to the CLG epitope or its variants; 4 donors 
responded to the wild-type Caucasion epitope sequence (CLG), and two of them 
cross recognized CLG variant 1. The data cannot clearly answer if the three 
peptides have the same immunogenicity, but the low frequency and low strength of 
CLG responses in Chinese overall indicate that this is a weak epitope and probably 
A201-restyricted only (Table 16). 
Another A2 epitope, YLL, derived from LMPl also elicited quite rare responses. 
Only two out of 133 donors recognized this epitope, and did so weakly, indicating 
that it is poorly immunogenic. In Chinese populations despite earlier data 
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suggesting that YLL might act as an A2-supertyp-restricted epitope. Other A2 
epitopes also showed different response patterns from those in Caucasians such as 
f l y and LLW [227], YVL, GLC and TLD [230]. We will discuss them in chapter 
4.4 and in chapter 4.6 
Several donors gave responses to two or more of peptides on the A2 epitoppe 
panel that are reportedly presented by different A2 subtypes. Many donors (table 
16; Hkcont 220, 241, 251，290，291，2114, 2145, 2146，2150，2160 and 2164) 
responded to different A2.01 restricted epitopes, and A203 restricted epitopes 
(VLK) at the same time, while Hkcont 248 and 2132 responded to both VLK 
(A203) and LTAg (A206). Not knowing the HLA types of these donors，we 
cannot say whether these epitopes are being presented by the same A2 subtype in 
such cases or if the donors are themselves positive for two A2 subtype alleles. 
However, given the unexpectedly high frequency of VLK responses over the 
predicted frequency based on A203 prevalence in the Chinese population, this 
increases the likelihood that VLK is not solely restricted through A203 but also 
can be presented through A201 or A206. 
Such examples of promiscuity of restricting alleles can be explained by the similar 
peptide motifs of the A2 subtypes [195]. Thus A2 restricted peptides have two 
dominant anchor residues, Leu or Met at position 2，and Val or Leu at position 9 
[82, 174，175, 255], the positions are thought to bind in the B and F pockets, 
respectively [81]. Other preference amino acids at the two sites are small or 
aliphatic hydrophobic residues (Ala, He, Val, Leu, Met, or Thr) [82，176，195]. 
This results in the concept of an HLA-A2 supertypes [174，175], minimally 
including A201, A202, A203, A204，A205, A206 and A207 [176，195]. However 
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we do not find clear evidence here for EBV peptides that act as supertype epitopes. 
Rather, A2 subtypes in the Chinese population appear to strongly affect epitope 
choice. So each epitope restricted by different A2 subtype has to be investigated 
separately, and the epitopes for vaccination must, therefore, take into account the 
A2 subtype expressed by the patients. 
4.3 Discussion of Other HLA Restricted Epitopes 
Some epitopes included in the panel because the relevant restricting allele was rare 
but present in Chinese gave predictably rare responses. The typical example was 
the B2704/06-restricted epitoope RRRW (from LMP2) [118]，where only 3 out of 
127 donors responded but where only � 5 - 6 was predicted to be positive for these 
alleles. Previously study showed the epitope is highly subtype-specific by HLA-
B2704. The same was true of epitopes such as YHL (B38 restricted) and VQP 
(B46 restricted) with rare observed and rare predicted frequencies of responders. 
The B40-restricted epitope lED from LMP2, as identified in B40-positive 
Caucasian, shows one or two amino acid changes in Chinese virus isolates to give 
the lEDSI sequence. Since these amino acid changes do not involve anchor sites, 
the immunogenicity of two epitopes could in theory be almost same [147]. Our 
results showed they indeed elicited similar results in Elispot assays with Chinese 
virus carriers, suggesting that lEDSI is indeed immunogenic. There is a similar 
situation with respect to another LMP2 epitope TYG, identified as A24-restricted 
in work with Caucasians, which exists in Chinese isolates as a variant sequence 
TYG-SL. However here the study identified 6 out of 8 donors who responded to 
TYG but did not recognize TYGSL, and 2 out of 4 TYGSL-reponders who did not 
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recognize TYG. The data suggested that the previous prediction of the same 
immunogenicity o f two epitopes m ay need to b e c orrected and t his n eeds to b e 
looked at again in future work where the donors are HLA-types for A24 and where 
the resident virus is sequenced across the A24 epitope-coding region of LMP2. 
The work with other epitopes on the panel did reveal unexpected examples of HLA 
supertype responses. For instance we included the HLA-A2301 restricted LMP2 
epitope, PYL even though this allele the HLA allele has a frequency of only 0.48% 
in the Chinese population, thus that we would expect only about 1 person with this 
type among our 133 donors. Nevertheless, our results showed that 9/133 donors 
recognized the epitope. We noted that A2301 is proposed as a member of the 
HLA-A24 superfamily which also includes A2402，A2403, A2404, A3001, 
A3002 and A3003. The supermotif of A24 supertype was proposed to include Y 
or F (or, less frequently, W, L, V，I, M, or T) at position 2 and F and I (or, less 
frequently, Y，W，L, or, M) at the C terminus (review in [177]). PYL satisfies the 
supertype motifs since the sequence of the epitope fits perfectly to the binding 
motif (Y at position 2 and I at the C terminus). Indeed, a most recent study proved 
PYL could be recognized by HLA-A2402 and HLA-A2301 alleles [256]. Thus 
most of positive PYL responders in the present study could be A2402-positive; 
indeed 5 out of 9 PYL positive donors (Hkcont 251, 277，2136, 2149, 2144) also 
responded to the A24-restricted peptide TYG and another PYL positive donors 
(Hkcont 2148) responded to the TYGSL variant. HLA-A2402 frequency (18%) is 
much higher than A2301 in Asians [257] and the existence of supertype-restricted 
CTL epitopes in such an important target protein as LMP2 has potentially practical 
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implications for the development of a therapeutic vaccine targeting NPC through 
boosting relevant CTL responses in patients of Chinese origin. 
Another epitope, VMS, which is restricted by HLA-A25 in Caucasians, also 
showed supertype restriction. Our data showed 5 donors responded to this epitope 
but less than one donor was expected to be A25-positive since the allele is very 
rare in Chinese. A25 is one member of the A1 supertype; other members of alleles 
in this family are Al , A26, and A32 [177]. Like A25, both A1 and A32 are very 
low (close to zero) in Chinese [154, 155]. Thus the positive donors in this study 
are very likely A26 note that 8% of Chinese are A26 positive (predicting 11 donors 
with this allele in our panel). The fact that 5 responders were identified suggests 
that VMS is a strong A26-restricted epitope in Southern Chinese 
Likewise the WTL peptide is reportedly B63-restricted in Caucasians [227] and its 
sequence accords well with the proposed B63 binding motif [258]; one HLA-B63 
restricted clone from the TAP-2 deficient donor showed specific response to this 
epitope [259]. The B63 frequency in Chinese is about 0.2% (predicting less than 1 
relevant donor in this study), but our data showed 12 out of 126 donors (9%) 
responded to this epitope. The allele is one of two closely related alleles, another 
is B62, and together they are the members of B15 supertype family [260]. About 
30% of Chinese are B15 positive [154, 155]. In Hong Kong donors, B62 occupy 
10%, while B63 only occupy less than 1% [154，155]. This strongly suggests that 
the epitope is B62-restricted epitope in Chinese, even though the Caucasian 
responder was B63 positive [259]. 
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In Chinese population, about 13% Chinese are B58 and this accords with our 
results showing that 19 out of 133 donors (14%) responded to the VSF epitope, 
often numerically dominant responses Implying that this a very strong epitope in 
all B58 donors rather than only in B5801 donors [147]. However there also exists a 
B58 supertype family include B58, B1516, B1517, B5701, B5702 [258, 261] and 
recent findings have shown that VSF is also well presented and strongly 
immunogenic in B57-positive Caucasians (AB.Rickinson, personal 
communication) 
4.4 Discussion of LMPl, LMP2, EBNAl Epitopes 
These epitopes were put together because their source antigens are expressed in 
most if not all NPC tumors. 
LMPl is well conserved in different EBV types [262]. The sequence of the protein 
in most Chinese virus isolates, which are predominantly type 1，shows 93.5% 
amino acid identity with B95.8 [263]. There were only two LMPl epitopes in this 
study, YLL and YLQ, and these were recognized only rarely. Only 2 donors had a 
response to YLL (22-197/10^), consistent with a previous study [145, 264]. The 
YLQ, epitope is conserved between Caucasian and Chinese EBV isolates. A 
previous study showed YLQ specific T cells were less than 0.001% in PBMCs but 
after in vitro stimulation with pulse peptide DCs, the frequency increased to 0.5% 
to 3.8% in Caucasians donors [264]. In the present study, the frequencies to the 
YLQ were 32-118/10^ The lower response strength and narrow response breadth 
(5 out of 133 donors) indicated the immunogenicity of the YLQ epitope is also 
weak. Our data support the idea that LMPl appears poorly immunogenic in man 
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for CDS T cell responses. Previous work showed that LMPl was non-
immunogenic in a murine model [249], possibly "due to LMPl transmembrane 
localization limiting its accessibility to the class IMHC pathway" [248；. 
In the context of NPC, LMP2 specific responses are of particular interest in Hong 
Kong [154, 155, 265]. The expression of LMP2 protein has not yet been proved 
in NPC tumor cells, but this is not the barrier for epitope-based therapy in this 
disease because LMP2A and 2B mRNA transcripts are readily detected in NPC 
biopsies [143]. Also NPC p atients h ad v ery h igh 1 evels o f s e rum a ntibodies t o 
LMP2 [146] and DCs loaded with LMP2 peptides are capable of eliciting epitope-
specific CTL responses in vitro [150]. Clinical trial proved such responses might 
lead to NPC tumor regression [151]. Thus LMP2 epitopes are therapeutically 
useful targets. 
There were 16 CD8+ T-cell epitopes from LMP2 in this study. In total, only 51% 
(68/133) donors recognized at least one of the epitopes. The immunogenicity of 
the epitopes (as defined by Elispot responses) varied significantly. The epitopes, 
SSCS (All) , TYG/TYGSL (A24) and lED/IEDSI (B40)，showed relatively high 
immunogenicity whereas most A2-restricted epitopes were weak. A possible 
exception was the FLY epitope that is highly conserved in the LMP2 gene of all 
Caucasian and Chinese EBV isolates, including the viruses present in the tumor 
cells of HD and NPC [225]. Response levels to FLY/A2 were 24-97/10^ PBMCs; 
similar to the LLW/A2 epitope (20-196/10^) in the population. In Caucasian 
donors, FLY responses at 168/10^ PBMCs aoppeared stronger than the responses 
to CLG and LLW in the same individuals [230]. The different response strength to 
FLY and LLW may reflect A2 subtype polymorphisms influencing epitope 
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Strength in this population. Responses to he LLS/A203 LMP2 epitope are very 
weak compare to two A203 restricted epitope, SLR and VLK, from other EBV 
latent antigens. The LTAg/A206 LMP2 epitope is apparently also poorly 
immunogenic. 
In total, our results showed the CTLs responses to LMP2 are quite weak in vivo. 
The frequencies are from 2 2 - 7 0 9 / 1 T h a t is, in the whole blood, only 
0.0022�0.070/0 PBMCs maybe are specific LMP2-specific CTLs. Previous work 
showed LCL-specific response to EBV comprises ll%-22% of total cellular 
response for adaptive cellular immunotherapy [141], but in healthy virus carriers, 
CTLs response to LMP2 often occupies only a minor component of the total EBV-
specific responses (4% of LCL-response) [141，266]. Furthermore, EBV-specific 
CTL responses in NPC patients are weaker than in healthy controls [149，2 67:. 
Interestingly, the A2-positive population has a slight higher risk of developing 
NPC [184, 185, 265] and most A2 restricted epitope responses to LMPl or LMP2 
from our data are very weak. The two findings may be related. Effective T cell 
therapy against NPC will need to amplify these weak responses selectively. 
Responses to the EBNAl-derived VLK epitope are relatively strong in southern 
Chinese. Earlier work has shown that EBNA-1 induced CTL responses are unable 
to recognize naturally infected EBNAl-expressing cells. The reason is the 
protein's internal G-Ar domain which give protects EBNAl from processing and 
presentiation by the HLA class I pathway [129]. But later studies revealed 
unexpectedly strong CD8+ T cell responses were actually detectable in HLA A203 
and B3501-positive humans, and these CTLs (to VLK and to a B35/HPV epitope 
repectively) recognized target cells expressing GAr-deleted but not full length 
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EBNAl [228, 268]. In fact the B35 epitope response is one of the strongest latent 
epitope responses observed to date，accounting for up to 5% of CD8+ T cells in 
primary infection [269]. Our data clearly proved the response in Southern Chinese 
to VLK is quite common and relatively stronger than other A2 restricted epitopes. 
Where do these EBNAl-specific CTLs come from? So far, there is no evidence 
for G-Ar-negative strains existing [261]. One possible explanation is cross 
priming [270, 271] since this pathway is important in the activation of immune 
response [272]. That is, dentritic cells (DCs) catch the released proteins from 
infected cells and re-present such exogenouly acquired Ags to CD8+ T cells via 
MHC class I pathway [269,273]. The cross priming involves catching fragments 
of apoptotic-infected cells, such as tumor cells or B cells or epithelial cells [274]. 
While LCL cells may be capable of cross priming，they are 1 00-300 times less 
efficient than DCs [275] and it is known that DCs can process and present EBNAl 
[276]. 
In the context of polyepitope vaccines targeting NPC and HD，the global vaccine 
should contain the minimum number of epitopes able to cover most populations in 
the world. Using the standard, SSCS is an ideal candidate for the Chinese 
population since we again proved almost 50% HLA-All donors responded to this 
epitope. Other epitopes, such as TYG (A2402, 22.4%), and lED/ lEDSI (B40， 
26.3%), also are relatively good c andidates, as are VMS, PYL, and WTL since 
they are restricted through relevant supertypes. 
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4.5 Discussion of EBNA2, EBNA3, and EBNA-LP epitopes 
Other latent epitopes studies included the YHL/B38 epitope from EBNA2. There 
are about 10% of B38 people in southern Chinese [154, 155], so our observation of 
9 positive responders out of 93 tested, with response levels at 30-88/10^ PBMCs 
suggests that the epitope is weak and is also highly B38 specific. 
Previous studies showed EBNA 3 family protein elicit the strongest reactivities in 
the Caucasians. This may also be the same in Chinese since the strongest responses 
observed in our study were to an EBNA3-derived epitope VSF/B58. 
To our knowledge, SLR/A203 is the first identified EBNA-LP epitope in Chinese 
donor s[147]. We found the response strength in the healthy population to be 49-
278/106. 
4.6 Discussion of LYTIC Epitopes 
Lytic proteins dominate the primary CDS T cell response in Caucasian infectious 
mononucleosis patients [311-313]; Prang found immunity directed against lytic 
cycle proteins [122, 277，278]. The response becomes weaker in persistent 
infection but, in Caucasians, always remains stronger in Elispot assays than 
responses to latent antigens [103 . 
There were 19 donors responding to one or more of the three lytic epitopes tested, 
GLC, YVL and TLD, all A201-restricted in Caucasians. The sequence of the 
GLC, accords well to the consensus sequence for A201 binding-peptides [82，255], 
and is regarded as an immunodominant epitope in Caucasians [218]. YVL is 
dominant over GLC in the primary response in IM patients but tends to be 
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subdominant in the memory of healthy carriers [227], but our data show that the 
YVL response is stronger than GLC response in healthy Chinese. So this is 
another A201 epitope whose response pattern in southern Chinese is different from 
that in Caucasians. 
From the results in table 23，TLD is interesting. This epitope is defined as A201 
restricted in Caucasians but is weaker than GLC and YVL [227]. However it 
induces almost the same response strength as GLC and YVL in this study, 
suggesting that TLD may be presented by a different subtype allele in Chinese 
populations. The allele could be A207-restricted because this allele's motif has L 
at position 2，and D at position 3 [195], TLD fits this motif perfectly at 2 and 3， 
while V at 9 should not be a problem because an A207 epitope, MAGE-3 271-279 
279] also has V at positition 9. So TLD responders in this study probably are 
A207 positive. Indeed, most of donors (17/19) responded to only one of the three 
lytic “A20r，Caucasian epitopes (table 16) so their restriction in Chinese 
populations is worthy of further study. 
So far, the understanding of CTL responses to lytic antigens remains fragmentary. 
The responses are very probably the main component of EBV control in acute 
infection. It may eliminate or control virus at an early stage, perhaps before the 
formation and release of mature virions, which may provide the second line of 
defense against the virus in vivo [153, 280]. However these responses are unlikely 
to be relevant to tumour targeting strategies. 
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4.7 Discussion of Summary 
Immunodominance exists among EBV epitopes [281, 282]. One of the known 
patterns of immunodominance is that individuals concentrate their reactivities 
against to 2-3 epitopes, one of which can be the strongest; and most of the 
strongest latent antigen-specific responses are directed towards epitopes from the 
EBNA3 proteins [112；. 
As in the table 22，most of the donors responded to 1-4 epitopes, we also can see 
that EBNA 3 family epitopes are relatively stronger (table 23); most of the 
responses to latent epitopes are also consistent with the status of persistent 
infection in healthy donors [103, 111]. HLA-B restricted epitope also have 
statistically stronger responses than that in HLA-A epitopes (Non-parameter test, 
data not shown). This is also consistent with previous intituitive speculation [167. 
However since our analysis was selective and not all the potentially immunogenic 
epitopes in all EBV latent proteins were included, it is not fair to draw firm 
conclusions. More work needs to be carried out if this issue of immunodominance 
is to be properly studied. 
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5 Chapter 5 Conclusion 
This study, for the first time, performed an analysis of extensive HLA class I 
restricted EBV epitope reactivities in southern Chinese. We revealed that the 
feature of epitope choices in specific Hong Kong population are diversified. 
In Al 1 population, almost all of IVT and AVF variants unlikely induce CTLs 
response in vivo. Thus again emphasized that higher HLA Al 1 may exert pressure 
on the epitope-loss in the population. Thus the variants may have evolved 
as immune escape mutants that enjoy a selective advantage in a highly A l l -
positive host population. In A2 population, some of the known A2 restricted 
epitopes are highly subtype specific; some are not such as FLY, LLW. There is no 
“pan，，A2 epitopes in the known A2 restricted epitopes. In contrast, Non-A2 and 
Non-All restricted epitopes, such as WTL, VMS, and PYL, 
have much higher frequencies of responses in Chinese than would be predicted 
from the expected from the representation of their known restricting alleles in the 
Chinese population, suggesting these are presented by related Chinese HLA class I 
alleles that are within the same "HLA supertype" family. 
Relatively lower immunogenicity of LMPl and LMP2 epitopes proved the 
necessary of selective reactivation of CTLs response to EBV malignancies, NPC 
and HD. On the context of diseases, SSCS, TYG, lED，FLY, LLW, YLQ RRRW 
of LMP epitopes are relatively good candidates. For design of global vaccine, 
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